

CITATION REPORT

List of articles citing

A controlled trial of renal denervation for resistant hypertension

DOI: 10.1056/nejmoa1402670

New England Journal of Medicine, 2014, 370, 1393-401.

Source: <https://exaly.com/paper-pdf/59726774/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1710	Gene silencing in DNA damage repair. 2004 , 61, 2168-72		5
1709	The Impact of Blood Pressure on Carotid Artery Stiffness and Wave Intensity in Patients with Resistant Hypertension after Renal Sympathetic Denervation. 2013 , 03,		
1708	Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. 2014 , 2014, 406960		282
1707	Commentary on recent guidelines for treating hypertension. 2014 , 10, 1069-72		10
1706	Antihypertensive drug therapy: a review based on recent guidelines. 2014 , 57, 1034		0
1705	Indications, implications and applications of renal denervation. Have we discovered something new?. 2014 , 10, 26-30		1
1704	Medicina Interna e Clinical Governance: quali proposte per il prossimo futuro?. 2014 , 2, 71		
1703	Renal denervation after the symplicity HTN-3 trial. 2014 , 10, 75-7		6
1702	South African hypertension practice guideline 2014. 2014 , 25, 288-94		88
1701	Diagnostic and therapeutic strategies for resistant arterial hypertension--focus on countries with emerging economies. 2014 , 115, 280-6		2
1700	Cardiac function and hypertension in patients with obstructive sleep apnea. 2014 , 189		1
1699	Moderator's view: renal denervation: the jury is still out and the verdict will be more complex than initially envisaged. 2014 , 29, 1124-6		1
1698	Renal denervation for resistant hypertension. <i>New England Journal of Medicine</i> , 2014 , 371, 184	59.2	28
1697	Effects of renal denervation on atrial arrhythmogenesis. 2014 , 10, 813-22		5
1696	Renal denervation in the treatment of resistant arterial hypertension. 2014 , 164, 515-8		3
1695	Resistant hypertension and renal denervation: what do the guidelines say? A nephrologist's perspective. 2014 , 6, 515-525		
1694	Letter by Wang regarding article, "renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?". 2014 , 115, e18		2

1693	Renal sympathetic denervation in the aftermath of Symplicity HTN-3. 2014 , 23, 256-61	5
1692	Potential reduction of interstitial myocardial fibrosis with renal denervation. 2014 , 3, e001353	34
1691	Kein Vorteil mit renaler Denervation. 2014 , 8, 30-30	
1690	Renal denervation therapy for resistant hypertension. 2014 , 16, 350	1
1689	[New ESH/ESC guidelines on arterial hypertension : what is new and what indications remain for renal denervation?]. 2014 , 39, 952-6	1
1688	The authors reply:. 2014 , 86, 1059-60	
1687	Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension. 2014 , 37, 1029-31	2
1686	Efficacy and safety of catheter-based radiofrequency renal denervation in stented renal arteries. 2014 , 7, 813-20	12
1685	'SYMPPLICITY: not all that simple' is, in fact, simple. 2014 , 86, 1060	
1684	The author replies:. 2014 , 86, 1060-1	1
1683	Renal nerves: time for reassessment of their role in hypertension?. 2014 , 27, 1245-7	3
1682	Renal Denervation Using an Irrigated Radiofrequency Ablation Catheter in Patients with Resistant Hypertension. 2014 , 22, 73-80	0
1681	Impact of baroreflex activation therapy on renal function--a pilot study. 2014 , 40, 371-80	38
1680	Antibodies in the pathogenesis of hypertension. 2014 , 2014, 504045	21
1679	Relation of ABO blood groups to coronary lesion complexity in patients with stable coronary artery disease. 2014 , 14, 561-2	2
1678	Arterial innervation in development and disease. 2014 , 6, 252ps9	25
1677	Is isolated systolic hypertension an indication for renal denervation?. 2014 , 5, 505	1
1676	What is the true incidence of renal artery stenosis after sympathetic denervation?. 2014 , 5, 311	5

1675	CarioPulse: EuroPCR 2014: the 25th Official Congress of the European Association of Percutaneous Cardiovascular Interventions. 2014 , 35, 2699			3
1674	Renale Denervation [Auswirkung auf Blutdruck und HbA1c. 2014 , 12, 124-128			
1673	Renal denervation: potential indications and review of trial data. 2014 , 14 Suppl 6, s38-40			2
1672	Renal denervation and blood pressure reduction in resistant hypertension: a systematic review and meta-analysis. 2014 , 1, e000092			4
1671	Renal denervation: results of a single-center cohort study. 2015 , 187, 36-41			2
1670	Rebuttal from Jens Jordan. 2014 , 592, 3945			
1669	Assessment and management of resistant hypertension. 2014 , 186, E689-97			8
1668	Renal nerve denervation--a hypertension bubble?. 2014 , 16, 472-4			3
1667	In reply to 'catheter-based renal denervation in ADPKD: just for pain control?'. 2014 , 64, 999-1000			
1666	Renal sympathetic denervation modulates ventricular electrophysiology and has a protective effect on ischaemia-induced ventricular arrhythmia. 2014 , 99, 1467-77			41
1665	Rebuttal from Markus P. Schlaich, Yusuke Sata and Murray D. Esler. 2014 , 592, 3947			
1664	Renal denervation for resistant hypertension?. <i>New England Journal of Medicine</i> , 2014 , 370, 1454-7	59.2	53	
1663	Baroreceptor stimulation for resistant hypertension: first implantation in France and literature review. 2014 , 107, 690-6			8
1662	CrossTalk opposing view: Which technique for controlling resistant hypertension? Carotid sinus stimulation. 2014 , 592, 3933-5			4
1661	Renal sympathetic denervation for treatment of resistant hypertension: Egyptian experience. 2014 , 27, 423-7			4
1660	Advances in therapeutic interventions for patients with pulmonary arterial hypertension. 2014 , 130, 2189-208			209
1659	Anatomy, Physiology, and Pathophysiology of Renal Circulation. 2014 , 1-32			1
1658	Rebuttal from L. E. K. Ratcliffe, W. Pijacka, F. D. McBryde, A. P. Abdala, D. J. Moraes, P. A. Sobotka, E. C. Hart, K. Narkiewicz, A. K. Nightingale and J. F. R. Paton. 2014 , 592, 3949-50			

1657	CrossTalk opposing view: Which technique for controlling resistant hypertension? Renal nerve ablation. 2014 , 592, 3937-40	5
1656	Baroreflex activation therapy for patients with drug-resistant hypertension. 2014 , 12, 955-62	6
1655	Where and when device therapy may be useful in the management of drug-resistant hypertension. 2014 , 16, 546	1
1654	The future of renal denervation in resistant hypertension. 2014 , 16, 494	12
1653	Antihypertensive treatments in obese patients: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial experience. 2014 , 32, 1402-4	
1652	Cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension and improving patients' adherence. 2014 , 32, 2357-8	6
1651	Interventional management in hypertension: where do we stand?. 2014 , 23, 444-8	
1650	Renal denervation in treatment-resistant hypertension - Oslo RDN, Symplicity HTN-3 and INSPIRED randomized trials. 2014 , 23, 135-7	4
1649	Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. 2014 , 32, 2411-21; discussion 2421	34
1648	Hyperresponders vs. nonresponder patients after renal denervation: do they differ?. 2014 , 32, 2422-7; discussion 2427	29
1647	Managing hypertension in patients with chronic kidney disease. 2014 , 27, 37-46	1
1646	Gastrointestinal intervention ameliorates high blood pressure through antagonizing overdrive of the sympathetic nerve in hypertensive patients and rats. 2014 , 3, e000929	24
1645	Catheter-based renal sympathetic denervation: limitations to and gaps in the evidence. 2014 , 29, 336-43	3
1644	Taking the hype out of hypertension. 2014 , 52, 109	
1643	If I had resistant hypertension. 2014 , 64, e3-6	2
1642	Renal nerve ablation after SYMPPLICITY HTN-3: confused at the higher level?. 2014 , 35, 1706-11	52
1641	Proteinuria in Hypertensive Nephropathy: A Review. 2014 , 04, 92-99	2
1640	SYMPPLICITY HTN 3: The death knell for renal denervation in hypertension?. 2014 , 2014, 94-8	11

1639	MR-guided high-focused ultrasound for renal sympathetic denervation-a feasibility study in pigs. 2014 , 2, 12	8
1638	Cross talk between renal and cardiac autonomic nerves: is this how renal denervation works?. 2014 , 25, 1257-8	2
1637	The kidney-heart connection during electrical storm: from bedside back to bench. 2014 , 99, 1451-2	2
1636	The renal artery conundrum: solving the puzzle of concomitant resistant hypertension and angiographic stenosis. 2014 , 175, 192	
1635	The link between renal denervation and reduction of cardiovascular risks: simplicity or not?. 2014 , 174, 732-3	2
1634	Increasing role of interventional cardiologists for peripheral vascular disease. 2014 , 39, 255-311	1
1633	Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. 2014 , 114, 1500-15	389
1632	Sympathetic stimulation of thiazide-sensitive sodium chloride cotransport in the generation of salt-sensitive hypertension. 2014 , 64, 178-84	55
1631	The autonomic nervous system and heart failure. 2014 , 114, 1815-26	295
1630	The autonomic nervous system and hypertension. 2014 , 114, 1804-14	306
1629	Hypertension: How should data from SYMPPLICITY HTN-3 be interpreted?. 2014 , 11, 375-6	15
1628	Renal denervation and Symplicity HTN-3: "Dubium sapientiae initium" (doubt is the beginning of wisdom). 2014 , 115, 211-4	39
1627	[Management of resistant hypertension. Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology]. 2014 , 43, 1325-31	11
1626	Experience with an innovative new Food and Drug Administration pathway for first-in-human studies: carotid baroreceptor amplification for resistant hypertension. 2014 , 7, 1328-30	4
1625	Blood pressure and autonomic responses to electrical stimulation of the renal arterial nerves before and after ablation of the renal artery. 2014 , 177, 669-71	5
1624	Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?. 2014 , 115, 400-9	55
1623	A historical perspective on peripheral reflex cardiovascular control from animals to man. 2014 , 99, 1017-26	2
1622	Endovascular intervention in renovascular disease: a pictorial review. 2014 , 5, 667-76	2

1621	Renal denervation in multiple renal arteries. 2014 , 44, 728-35	12
1620	CrossTalk opposing view: Which technique for controlling resistant hypertension? Carotid chemoreceptor denervation/modulation. 2014 , 592, 3941-4	8
1619	Chemical renal denervation by vincristine: the role of the flow rate of delivery. 2014 , 37, 1336-42	5
1618	Resistant hypertension in diabetes mellitus. 2014 , 14, 516	6
1617	Resistant or refractory hypertension: are they different?. 2014 , 16, 485	15
1616	An Update on Treatment Options for Drug Resistant Hypertension. 2014 , 8, 1	
1615	63rd Annual Scientific Sessions of the American College of Cardiology: 29-31 March 2014; Washington, DC, USA. 2014 , 14, 327-31	
1614	[Renal denervation by trans-radial access for resistant hypertension]. 2014 , 63, 460-4	1
1613	Current perspectives on systemic hypertension in heart failure with preserved ejection fraction. 2014 , 16, 545	22
1612	Transvenous stimulation of the renal sympathetic nerves increases systemic blood pressure: a potential new treatment option for neurocardiogenic syncope. 2014 , 25, 1115-8	11
1611	Le syndrome cardio-renal : diagnostic, physiopathologie et prise en charge. 2014 , 23, 585-594	2
1610	"Hold the catheters"--renal denervation may not be the answer to the management of resistant or hard-to-treat hypertension. 2014 , 8, 758-9	
1609	Apparent treatment-resistant hypertension and chronic kidney disease: another cardiovascular-renal syndrome?. 2014 , 21, 489-99	5
1608	Resistant hypertension and renal denervation. Considerations on the results of the SYMPPLICITY HTN-3 trial. 2014 , 67, 881-2	1
1607	Ambulatory blood pressure may be designed as the primary efficacy outcome in clinical trials on renal denervation. 2014 , 176, 1262-3	
1606	Diabetic kidney disease: a report from an ADA Consensus Conference. 2014 , 64, 510-33	324
1605	Diabetic kidney disease: a report from an ADA Consensus Conference. 2014 , 37, 2864-83	539
1604	Methodological standardization for the pre-clinical evaluation of renal sympathetic denervation. 2014 , 7, 1184-93	46

1603	Obesity-associated hypertension: recent progress in deciphering the pathogenesis. 2014 , 64, 215-21	82
1602	Renal denervation for resistant hypertension: not dead yet. 2014 , 64, 1088-91	9
1601	Resistant hypertension and healthy lifestyle: impact on prognosis. 2014 , 64, 459-60	1
1600	Renal denervation: should we still hang in there?. 2014 , 176, 1255-6	5
1599	Renal denervation in hypertension: simplicity, or complexity?. 2014 , 107, 421-3	1
1598	Electrical stimulation of the renal arterial nerves does not unmask the blindness of renal denervation procedure in swine. 2014 , 176, 1061-3	9
1597	Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. 2014 , 8, 593-8	85
1596	Mild hypertension in people at low risk. 2014 , 349, g5432	32
1595	Risques cardio-métaboliques: Dénervation rénale dans l'hypertension artérielle résistante : l'essai SYMPPLICITY HTN-3. 2014 , 8, 329	
1594	Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement. 2014 , 64, 922-37	70
1593	Hipertensión arterial resistente y denervación renal. Reflexiones tras el estudio Symplicity HTN-3. 2014 , 67, 881-882	2
1592	Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study. 2014 , 130, 1346-52	19
1591	The effect of percutaneous renal denervation on muscle sympathetic nerve activity in hypertensive patients. 2014 , 176, 8-12	25
1590	Pressure natriuresis and the renal control of arterial blood pressure. 2014 , 592, 3955-67	83
1589	Advances in clinical cardiology. 2014 , 31, 837-60	4
1588	Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy?. 2014 , 64, 644-6	52
1587	Invasive treatment of resistant hypertension: present and future. 2014 , 16, 488	5
1586	Renale Denervierung und Hypertonie. 2014 , 9, 350-356	

1585	Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. 2014 , 8, 743-57	38
1584	Hypertension Treatment for Patients with Advanced Chronic Kidney Disease. 2014 , 8, 1	4
1583	Do current clinical trials meet society's needs?: a critical review of recent evidence. 2014 , 64, 1615-28	44
1582	Renal denervation--a valid treatment option despite SYMPLICITY HTN-3. 2014 , 11, 638	8
1581	Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. 2014 , 115, 79-96	322
1580	Autonomic blockade improves insulin sensitivity in obese subjects. 2014 , 64, 867-74	32
1579	Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension. 2014 , 114, 856-61	17
1578	Renal denervation after Symplicity HTN-3: an update. 2014 , 16, 460	21
1577	Renale Denervation bei therapierefraktärer arterieller Hypertonie verfehlt in der SYMPLICITY-HTN-3-Studie den primären Wirksamkeitsendpunkt. 2014 , 8, 214-215	
1576	Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. 2014 , 8, 223-230	22
1575	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. 2014 , 35, 1752-9	186
1574	Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. 2014 , 64, 565-72	55
1573	Top 10 cardiovascular therapies and interventions for the next decade. 2014 , 11, 671-83	29
1572	Evaluaci3n econ3mica de la denervaci3n simplicica renal: simplicidad, todav3a no. 2014 , 21, 152-153	
1571	Innervation patterns may limit response to endovascular renal denervation. 2014 , 64, 1079-87	91
1570	Ethnicity and sympathetic tone: predictors of the blood pressure response to renal denervation?. 2014 , 11, 638	3
1569	Decade in review--hypertension: the past decade in hypertension--facts, hopes, and hypes. 2014 , 11, 633-5	5
1568	Sham controls in medical device trials. <i>New England Journal of Medicine</i> , 2014 , 371, 892-3	59.2 37

1567	Atrial fibrillation ablation: translating basic mechanistic insights to the patient. 2014 , 64, 823-31	58
1566	Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPPLICITY HTN-3. 2014 , 64, 1071-8	130
1565	Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study-PRAGUE-15. 2014 , 56, e235-e239	8
1564	Hypothalamic control of hepatic lipid metabolism via the autonomic nervous system. 2014 , 28, 673-84	19
1563	Renal denervation for resistant hypertension-the Symplicity HTN-1 study - Authors' reply. 2014 , 383, 1885-6	4
1562	Lack of blood pressure-lowering effect of renal denervation in a drug-naïve patient with pronounced arterial stiffening. 2014 , 127, e3-4	6
1561	Renal denervation for refractory ventricular arrhythmias. 2014 , 24, 206-13	21
1560	[Denervation of the renal arteries: an old story?]. 2014 , 39, 245-7	
1559	Potential future denervation targets. 2014 , 6, 569-579	
1558	Report of the American College of Cardiology (ACC) Scientific Sessions 2014, Washington, DC. 2014 , 78, 1311-6	0
1557	Raising Lazarus: reassessing renal denervation after SIMPLICITY HTN 3. 2014 , 6, 503-505	
1556	Journal Club. 2014 , 85, 1251-1252	
1555	Renal artery stenosis following renal denervation: a matter of concern. 2014 , 32, 2101-5	20
1554	Diagnosis and management of fibromuscular dysplasia. 2014 , 32, 2098	1
1553	Reply: diagnosis and management of fibromuscular dysplasia. 2014 , 32, 2098-9	
1552	Reply: contribution of the ABP-International study to the definition of night-time tachycardia. 2014 , 32, 2101	0
1551	Contribution of the ABP-International study to the definition of night-time tachycardia. 2014 , 32, 2099-100	2
1550	What does the future hold for renal denervation?. 2014 , 35, 1695-6	3

1549	Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). 2014 , 93, e162	36
1548	Denervaci3n renal por cat3ter como tratamiento para la hipertensi3n pulmonar: ¿esperanza o espejismo?. 2015 , 68, 551-553	3
1547	Renal Denervation: A Potential Novel Treatment for Type 2 Diabetes Mellitus?. 2015 , 94, e1932	8
1546	The influence of catheter-based renal sympathetic denervation on renal function and renal arteries. 2015 , 57, e245-e250	
1545	Central arteriovenous anastomosis and hypertension - Authors' reply. 2015 , 386, 1821-2	1
1544	An update of the expert consensus statement of the Czech Hypertension Society on renal denervation in resistant hypertension. 2015 , 57, e187-e189	5
1543	Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial. 2015 , 9, 959-65	3
1542	Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. 2015 , 66, 1766-1775	126
1541	Neue Studien zur Hypertonie. 2015 , 11, 237-249	
1540	Drug adherence monitoring in clinical trials: a necessity for a correct assessment of the efficacy and safety of antihypertensive therapies. 2015 , 33, 2395-8	8
1539	Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right. 2015 , 38, 447-54	7
1538	De novo renal artery stenosis after renal sympathetic denervation. 2015 , 17, 242-3	3
1537	Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications. 2015 , 45, 1367-75	116
1536	SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients -. 2015 , 79, 1222-9	76
1535	Renal artery denervation: modulation of the autonomic nervous system to treat atrial fibrillation. 2015 , 283-292	
1534	Research Roundup. 2015 , 10, 64-65	
1533	[Programs for Continuing Medical Education: A session; 4. Diagnosis and novel therapies of refractory hypertension]. 2015 , 104, 496-501	
1532	[Hypertension: The Points of Management of Hypertension for All Physicians--Based on the JSH 2014 Hypertension Guidelines--. Topics: X. Patients eligible for renal denervation and PTRAs--from the results of SYMPLICITY HTN-3 and CORAL trial]. 2015 , 104, 275-81	

1531	Renal Denervation in Heart Failure: A New Therapeutic Paradigm. 2015 , 9, 101-4	2
1530	Renal denervation as treatment of resistant hypertension. 2015 , 145, 131-135	
1529	Interventionelle Therapie bei schwer einstellbarer Hypertonie. 2015 , 11, 400-406	
1528	Commentary on highlighted late breaking trials in interventional cardiology at ESC, VIVA, TCT, and AHA 2013. 2015 , 85, 95-103	
1527	Post mortem study of the depth and circumferential location of sympathetic nerves in human renal arteries--implications for renal denervation catheter design. 2015 , 86, E32-7	10
1526	Resistant Hypertension and Renal Nerve Denervation. 2015 , 11, 240-4	7
1525	Intrathecal Clonidine via Lumbar Puncture Decreases Blood Pressure in Patients With Poorly Controlled Hypertension. 2015 , 18, 499-507; discussion 507	2
1524	Baroreflex activation therapy in patients with end-stage renal failure: proof of concept. 2015 , 33, 2344-9	12
1523	Electrical Stimulation of Vascular Autonomic Nerves: Effects on Heart Rate, Blood Pressure, and Arrhythmias. 2015 , 38, 825-30	8
1522	Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension. 2015 , 33, 181-6	41
1521	Blood pressure variability after catheter-based renal sympathetic denervation in patients with resistant hypertension. 2015 , 33, 2512-8	17
1520	Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. 2015 , 33, 2519-25	32
1519	Health-related quality of life and blood pressure 12 months after renal denervation. 2015 , 33, 2350-8	5
1518	Influence of pseudo-resistance on the effect of renal denervation on 24-hour ambulatory blood pressure levels. 2015 , 86, E126-30	1
1517	Design and participant baseline characteristics of 'A Clinical Trial of Intensive Dialysis': the ACTIVE Dialysis Study. 2015 , 20, 257-65	16
1516	Chronic bilateral renal denervation reduces cardiac hypertrophic remodelling but not β adrenergic responsiveness in hypertensive type 1 diabetic rats. 2015 , 100, 628-39	9
1515	Renal denervation for the treatment of hypertension: Making a new start, getting it right. 2015 , 86, 855-63	3
1514	Central arteriovenous anastomosis for hypertension: it is not all about sympathomodulation. 2015 , 11, 503-6	9

1513	New developments in the pathogenesis of obesity-induced hypertension. 2015 , 33, 1499-508	56
1512	Impact of number of prescribed medications on visit-to-visit variability of blood pressure: implications for design of future trials of renal denervation. 2015 , 33, 2359-67	5
1511	. 2015 ,	
1510	Short-term safety and efficiency of cryoablation for renal sympathetic denervation in a swine model. 2015 , 128, 790-4	6
1509	Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements. 2015 , 11, 61-77	2
1508	RESISTANT ARTERIAL HYPERTENSION: IS THE CONSENSUS BETWEEN CONSERVATIVE AND INTERVENTIONAL THERAPY POSSIBLE?. 2015 , 11, 182-189	
1507	References. 2015 , 123-134	
1506	Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!. 2015 , 2, 3	5
1505	Renal denervation for the management of resistant hypertension. 2015 , 8, 57-69	9
1504	Peregrine System Infusion Catheter for Perivascular Renal Denervation1. 2015 , 9,	
1503	A clinician's perspective of the role of renal sympathetic nerves in hypertension. 2015 , 6, 75	6
1502	Neural regulation of the kidney function in rats with cisplatin induced renal failure. 2015 , 6, 192	19
1501	Device-based approaches for renal nerve ablation for hypertension and beyond. 2015 , 6, 193	10
1500	The renal nerves in chronic heart failure: efferent and afferent mechanisms. 2015 , 6, 224	19
1499	Brain Gβ2 -subunit proteins and the prevention of salt sensitive hypertension. 2015 , 6, 233	1
1498	The role of the renal afferent and efferent nerve fibers in heart failure. 2015 , 6, 270	19
1497	An update on renal artery denervation and its clinical impact on hypertensive disease. 2015 , 2015, 607079	5
1496	Implications of Renal Denervation Therapy in Patients with Sleep Apnea. 2015 , 2015, 408574	3

1495	Microchannel Electrode Stimulation of Deep Peroneal Nerve Fascicles Induced Mean Arterial Depressor Response in Hypertensive Rats. 2015 , 2, 55-62	3
1494	Iperensione arteriosa: il ruolo dell'Internista. 2015 , 3, 1	
1493	Overtreatment. 2015 ,	
1492	Hypertension in minority populations: new guidelines and emerging concepts. 2015 , 22, 145-53	21
1491	Renal denervation of the native kidneys for drug-resistant hypertension after kidney transplantation. 2015 , 8, 79-81	4
1490	Marfan Sartan: a randomized, double-blind, placebo-controlled trial. 2015 , 36, 2160-6	134
1489	Management of ventricular arrhythmias in structural heart disease. 2015 , 127, 549-59	1
1488	Inferences Beyond a Study Design's Grasp: A Cautionary Case Study From the Recent Renal Sympathetic Denervation Literature. 2015 , 49, 86-92	2
1487	Managing Treatment-Resistant Patients. 2015 , 22 Suppl 1, S11-3	1
1486	Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. 2015 , 65, 5-15	16
1485	Role of renal sensory nerves in physiological and pathophysiological conditions. 2015 , 308, R79-95	92
1484	Renal denervation for the treatment of atrial fibrillation in hypertensive patients or beyond?. 2015 , 189, 59-60	1
1483	Renal Sympathetic Denervation. 2015 , 69-81	0
1482	Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. 2015 , 104, 1064-71	17
1481	Brain-derived neurotrophic factor as a marker for immediate assessment of the success of renal sympathetic denervation. 2015 , 65, 1151-3	15
1480	Renal denervation therapy for hypertension: pathways for moving development forward. 2015 , 9, 341-50	29
1479	Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. 2015 , 9, 397-402	31
1478	Atrial Remodeling Following Catheter-Based Renal Denervation Occurs in a Blood Pressure- and Heart Rate-Independent Manner. 2015 , 8, 972-80	31

1477	2014 update on interventional cardiology. 2015 , 68, 324-30	
1476	Drug therapy for the patient with resistant hypertension. 2015 , 11, 191-202	1
1475	Drug resistant hypertension [No simple way out. 2015 , 40, 66-76	6
1474	Cardiac innervation and sudden cardiac death. 2015 , 116, 2005-19	196
1473	Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. 2015 , 65, 1202-8	150
1472	Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension. 2015 , 131, 2079-91	61
1471	Renal denervation: back to reality, finally!. 2015 , 1, 57	
1470	VLSI circuits for bidirectional interface to peripheral and visceral nerves. 2015 , 2015, 2163-6	1
1469	Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right. 2015 , 17, 743-50	14
1468	Renal glucose release during hypoglycemia is partly controlled by sympathetic nerves - a study in pigs with unilateral surgically denervated kidneys. 2015 , 3, e12603	5
1467	Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials. 2015 , 66, 2757-2766	38
1466	Sham Surgery Research. 2015 , 10, 496-8	3
1465	Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study. 2015 , 8, e002837	71
1464	Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. 2015 , 66, 1130-7	34
1463	Beyond blood pressure: percutaneous renal denervation for the management of sympathetic hyperactivity and associated disease states. 2015 , 4, e001415	12
1462	Circumferential targeted renal sympathetic nerve denervation with preservation of the renal arterial wall using intra-luminal ultrasound. 2015 ,	
1461	Treatment of Atrial and Ventricular Arrhythmias Through Autonomic Modulation. 2015 , 1, 496-508	19
1460	Renal denervation for the treatment of resistant hypertension: review and clinical perspective. 2015 , 309, F583-94	36

1459	Impact of Uncontrolled Hypertension on Atrial Fibrillation Ablation Outcome. 2015 , 1, 164-173	24
1458	Impact of renal sympathetic denervation on home blood pressure monitoring in well defined patients with resistant hypertension. 2015 , 12, 23-27	
1457	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence. 2015 , 1, 48-56	6
1456	Transcatheter Renal Sympathetic Denervation: Chasing a Chimera or a Matter of Technological Improvements?. 2015 , 131, 186-8	4
1455	Hypertension and new treatment approaches targeting the sympathetic nervous system. 2015 , 21, 20-4	12
1454	The year in cardiology 2014: prevention. 2015 , 36, 214-8	4
1453	Long-term effects of baroreflex activation therapy on glucose metabolism. 2015 , 52, 829-35	11
1452	Cardiovascular news 2013/2014. 2015 , 215, 33-42	
1451	Renal denervation for resistant hypertension. 2015 , 34, 125-35	7
1450	Reverse cardiac remodeling after renal denervation: Atrial electrophysiologic and structural changes associated with blood pressure lowering. 2015 , 12, 982-90	45
1449	Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation. 2015 , 65, 401-6	31
1448	Cardiorenal axis and arrhythmias: Will renal sympathetic denervation provide additive value to the therapeutic arsenal?. 2015 , 12, 1080-7	9
1447	Is the failure of SYMPPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?. 2015 , 9, 140-9	25
1446	Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. 2015 , 18, 76-87	4
1445	Mechanisms of renal sympathetic activation in renovascular hypertension. 2015 , 100, 496-501	35
1444	2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. 2015 , 78, 1-47	140
1443	The sympathetic nervous system in hypertension: back to the future?. 2015 , 17, 11	40
1442	Denervation of the renal arteries in metabolic syndrome: the DREAMS-study. 2015 , 65, 751-7	37

1441	Potential relief for refractory angina. <i>New England Journal of Medicine</i> , 2015 , 372, 566-7	59.2	1
1440	Comparison of histopathologic analysis following renal sympathetic denervation over multiple time points. 2015 , 8, e001813		38
1439	Renal denervation attenuates progression of atherosclerosis in apolipoprotein E-deficient mice independent of blood pressure lowering. 2015 , 65, 758-65		14
1438	Overcoming the three biases obscuring the science of renal denervation in humans: big-day bias, check-once-more bias and I-will-take-it-now bias. 2015 , 25, 116-8		10
1437	Update in cardiology: vascular risk and cardiac rehabilitation. 2015 , 68, 136-43		2
1436	Impact of multi-electrode renal sympathetic denervation on short-term blood pressure variability in patients with drug-resistant hypertension. Insights from the EnligHTN I study. 2015 , 180, 237-42		13
1435	Novedades en cardiología: riesgo vascular y rehabilitación cardíaca. 2015 , 68, 136-143		5
1434	Cardiovascular news 2013/2014. 2015 , 215, 33-42		
1433	Renal Denervation After SYMPLICITY HTN-3: Where Do We Go?. 2015 , 31, 642-8		9
1432	Renal denervation in treatment-resistant hypertension: a reappraisal. 2015 , 21, 48-52		11
1431	Renal denervation for treatment of drug-resistant hypertension. 2015 , 25, 107-15		39
1430	Renal denervation. 2015 , 26, 95-105		7
1429	Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. 2015 , 385, 1634-41		121
1428	Central arteriovenous anastomosis in resistant hypertension?. 2015 , 385, 1596-7		5
1427	The crosstalk between the kidney and the central nervous system: the role of renal nerves in blood pressure regulation. 2015 , 100, 479-84		33
1426	The ROX coupler: creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature. 2015 , 85, 880-6		22
1425	Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. 2015 , 385, 1957-65		356
1424	Renal denervation superior to drug therapy in hypertension. 2015 , 385, 1922-4		6

1423	Renal sympathetic denervation for treatment of ventricular arrhythmias: a review on current experimental and clinical findings. 2015 , 104, 535-43	10
1422	What underlies the prolonged hypotensive effect of catheter-based renal denervation in humans?. 2015 , 65, 276-7	1
1421	Antiarrhythmic therapy in 2014: Contemporary approaches to treating arrhythmias. 2015 , 12, 68-9	16
1420	The year in cardiology 2014: peripheral circulation. 2015 , 36, 591-7	6
1419	Antihypertensive therapy in 2014: Linking pathophysiology to antihypertensive treatment. 2015 , 12, 77-9	4
1418	Reinnervation following catheter-based radio-frequency renal denervation. 2015 , 100, 485-90	25
1417	Renal allograft fibrosis: biology and therapeutic targets. 2015 , 15, 863-86	52
1416	Norepinephrine stimulates the epithelial Na ⁺ channel in cortical collecting duct cells via α -adrenoceptors. 2015 , 308, F450-8	18
1415	[Benefit assessment of medical devices]. 2015 , 58, 240-7	5
1414	Renal denervation for resistant hypertension and beyond. 2015 , 22, 133-9	4
1413	Revisiting renovascular imaging for renal sympathetic denervation: current techniques and applications. 2015 , 25, 444-53	4
1412	Is FAME 2 a breakthrough for PCI in stable coronary disease?. 2015 , 104, 283-7	6
1411	New approaches in the treatment of hypertension. 2015 , 116, 1074-95	159
1410	Thiazide Diuretics in Chronic Kidney Disease. 2015 , 17, 13	21
1409	The Baroreflex in Hypertension. 2015 , 17, 19	13
1408	First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. 2015 , 65, 766-74	139
1407	Catheter-based ultrasound technology for image-guided thermal therapy: current technology and applications. 2015 , 31, 203-15	23
1406	Radiofrequency and Irrigated Ablation: Principles and Potential for Renal Artery Denervation (RDN) in the Treatment of Resistant Arterial Hypertension. 2015 , 147-154	

1405	Renal Sympathetic Denervation for the Treatment of Ventricular Arrhythmias: A Lesson in Not Throwing Out the Baby With the Bathwater?. 2015 , 8, 991-3	1
1404	Blood Pressure Goals and Targets in the Elderly. 2015 , 17, 394	7
1403	Hypertension: Introduction, Types, Causes, and Complications. 2015 , 635-653	2
1402	Management of hypertension in chronic kidney disease. 2015 , 11, 555-63	43
1401	Electrical carotid sinus stimulation: chances and challenges in the management of treatment resistant arterial hypertension. 2015 , 17, 587	5
1400	Renal Denervation for Drug-Resistant Hypertension: There Is Still Hope. 2015 , 16, 202-3	1
1399	Blinding in pharmaceutical clinical trials: An overview of points to consider. 2015 , 43, 155-63	7
1398	Resistant hypertension: a volemic or nervous matter?. 2015 , 9, 408-9	5
1397	Design of renal denervation studies not confounded by antihypertensive drugs. 2015 , 9, 337-40	5
1396	Renal Sympathetic Denervation: Looking Beyond Hypertension. 2015 , 8, 981-3	1
1395	Personalized hypertension management in practice. 2015 , 12, 297-311	1
1394	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium. 2015 , 66, 278-307	128
1393	Spike rate of multi-unit muscle sympathetic nerve fibers after catheter-based renal nerve ablation. 2015 , 9, 794-801	5
1392	Catheter-based Renal Denervation as a Treatment for Pulmonary Hypertension: Hope or Hype?. 2015 , 68, 551-3	4
1391	Event Rates in Randomized Clinical Trials Evaluating Cardiovascular Interventions and Devices. 2015 , 116, 355-63	4
1390	Next generation renal denervation: chemical "perivascular" renal denervation with alcohol using a novel drug infusion catheter. 2015 , 16, 221-7	30
1389	Renal sympathetic denervation using an externally irrigated radiofrequency ablation catheter for treatment of resistant hypertension - Acute safety and short term efficacy. 2015 , 67, 207-13	
1388	Management of Hypertension in the Elderly. 2015 , 9, 1	

- 1387 Renal sympathetic denervation for resistant hypertension: a transiently sustained placebo effect?. **2015**, 29, 396-7
- 1386 A device to narrow the coronary sinus for angina. *New England Journal of Medicine*, **2015**, 372, 1967-8 59.2 3
- 1385 Transcatheter Structural Heart Interventions for the Treatment of Chronic Heart Failure. **2015**, 8, e001943 7
- 1384 [Renal denervation: long-term Swiss experiences]. **2015**, 104, 27-31 2
- 1383 Renal Denervation for Resistant Hypertension: Past, Present, and Future. **2015**, 17, 65 5
- 1382 Validation of renal artery dimensions measured by magnetic resonance angiography in patients referred for renal sympathetic denervation. **2015**, 22, 1106-14 1
- 1381 [Post-denervation renal artery stenosis - a matter of concern?]. **2015**, 64, 237-40
- 1380 The sympathetic nervous system alterations in human hypertension. **2015**, 116, 976-90 335
- 1379 Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium. **2015**, 36, 1851-77 26
- 1378 Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes. **2015**, 10, 1136-44 29
- 1377 Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. **2015**, 24, 263-74 51
- 1376 Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity?. **2015**, 309, H244-58 57
- 1375 A cross-sectional imaging study to identify organs at risk of thermal injury during renal artery sympathetic denervation. **2015**, 197, 235-40 4
- 1374 Renal Denervation Prevents Immune Cell Activation and Renal Inflammation in Angiotensin II-Induced Hypertension. **2015**, 117, 547-57 146
- 1373 The Role of Central Nervous System Mechanisms in Resistant Hypertension. **2015**, 17, 58 21
- 1372 Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review. **2015**, 17, 59 42
- 1371 Catheter-Based Radiofrequency Renal Denervation: Location Effects on Renal Norepinephrine. **2015**, 28, 909-14 62
- 1370 Selective proximal renal denervation guided by autonomic responses evoked via high-frequency stimulation in a preclinical canine model. **2015**, 8, 25

1369	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension. 2015 , 6, 9	7
1368	Advantages of Ambulatory Blood Pressure Monitoring in Assessing the Efficacy of Antihypertensive Therapy. 2015 , 4, 5-17	6
1367	Renal nerve stimulation leads to the activation of the Na ⁺ /H ⁺ exchanger isoform 3 via angiotensin II type I receptor. 2015 , 308, F848-56	35
1366	Comparison of Saline-Irrigated Catheter vs. Temperature-Controlled Catheter for Renal Denervation in a Canine Model. 2015 , 28, 1434-43	10
1365	Renal denervation in resistant arterial hypertension: Effects on neurohormonal activation and cardiac natriuretic peptides. 2015 , 184, 574-575	1
1364	Renal denervation--hypes and hopes. 2015 , 33, 141-4	2
1363	Management of pain in autosomal dominant polycystic kidney disease and anatomy of renal innervation. 2015 , 193, 1470-8	25
1362	Misconceptions and facts about treating hypertension. 2015 , 128, 450-5	5
1361	Informed choice in screening needs more than information. 2015 , 385, 1597-9	19
1360	Renal denervation for resistant hypertension. 2015 , 34, 125-135	5
1359	Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension. 2015 , 7, 285ra65	46
1358	Different responses of arterial blood pressure to electrical stimulation of the renal artery in patients with resistant hypertension. 2015 , 190, 296-8	6
1357	Catecholamine excess: pseudopheochromocytoma and beyond. 2015 , 22, 218-23	13
1356	Interventional and device-based autonomic modulation in heart failure. 2015 , 11, 337-48	14
1355	Stent-assisted coil embolization for a traumatic pseudoaneurysm of the visceral aortic segment. 2015 , 26, 451-3	
1354	Reply: A mechanistic explanation for the minimal impact of renal denervation on 24-h ambulatory blood pressure in SIMPLICITY HTN-3. 2015 , 65, 959-60	2
1353	Acute renal failure after renal denervation. 2015 , 26, 450-1	1
1352	European Society of Cardiology launches Council on Hypertension. 2015 , 36, 532-3	

1351	[Interventional strategies in hypertension management]. 2015 , 56, 240-7	1
1350	[Therapy-resistant hypertension]. 2015 , 56, 195-6, 198-202	0
1349	Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation. 2015 , 104, 79-84	22
1348	Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. 2015 , 104, 672-8	35
1347	Catheter-based renal denervation reduces atrial nerve sprouting and complexity of atrial fibrillation in goats. 2015 , 8, 466-74	49
1346	Renal Denervation in Heart Failure. 2015 , 17, 17	5
1345	Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 9, 453-98	39
1344	Renal Sympathetic Denervation by CT-scan-Guided Periarterial Ethanol Injection in Sheep. 2015 , 38, 977-84	2
1343	The heart is lost without the brain - the autonomic perspective. 2015 , 100, 345-7	
1342	2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension. 2015 , 21, 2	25
1341	Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists. 2015 , 75, 473-85	12
1340	Vagal modulation of hypertension. 2015 , 17, 532	11
1339	Actualizaci3n en cardiolog3a intervencionista 2014. 2015 , 68, 324-330	6
1338	Neuromatous regeneration as a nerve response after catheter-based renal denervation therapy in a large animal model: immunohistochemical study. 2015 , 8,	17
1337	Renal denervation: Not as easy as it looks. 2015 , 7, 285fs18	16
1336	Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review. 2015 , 162, 630-8	236
1335	Cardiorenal syndrome in chronic kidney disease. 2015 , 24, 154-62	23
1334	Lipids, blood pressure and kidney update 2014. 2015 , 95-96, 111-25	70

1333	The setback of renal denervation should not backfire on sympathetic overactivity in hypertension. 2015 , 65, 1322-1323	4
1332	Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects. 2015 , 65, 1209-16	47
1331	Hypertension: Renal denervation-promising data from the DENERHTN trial. 2015 , 11, 258-60	4
1330	Hypertension. 2015 , 386, 801-12	410
1329	12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPPLICITY HTN-3 trial. 2015 , 65, 1314-1321	78
1328	Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 65, 1372-407	76
1327	Effect of renal sympathetic denervation on the progression of paroxysmal atrial fibrillation in canines with long-term intermittent atrial pacing. 2015 , 17, 647-54	26
1326	Blood pressure decrease in spontaneously hypertensive rats following renal denervation or dopamine hydroxylase inhibition with etamicastat. 2015 , 38, 605-12	19
1325	Frequency of renal artery stenosis after renal denervation in patients with resistant arterial hypertension. 2015 , 115, 1545-8	15
1324	Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 65, 1998-2038	97
1323	Aldosterone antagonists and renal denervation: friends or foes?. 2015 , 65, 280-2	8
1322	Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 131, e435-70	80
1321	[Renal denervation as treatment of resistant hypertension]. 2015 , 145, 131-5	
1320	Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. 2015 , 116, 991-1006	571
1319	Influence of Renal Sympathetic Denervation on Cardiac Extracellular Matrix Turnover and Cardiac Fibrosis. 2015 , 28, 1285-92	13
1318	[Renal artery stenosis--new insights and developments]. 2015 , 140, 184-7	1
1317	Renal denervation: unde venis et quo vadis?. 2015 , 187, 237-47	1
1316	Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease. 2015 , 66, 998-1005	34

1315	Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. 2015 , 5, e008951	12
1314	Gastric electrical stimulation treatment of type 2 diabetes: effects of implantation versus meal-mediated stimulation. A randomized blinded cross-over trial. 2015 , 3, e12456	8
1313	Consider mineralocorticoid receptor antagonists as add-on therapy in treatment-resistant hypertension. 2015 , 31, 345-349	
1312	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPPLICITY HTN-3 trial. 2015 , 9, 769-779	27
1311	Renal Denervation: Where to Now?. 2015 , 17, 116	
1310	Impact of sympathetic renal denervation: a randomized study in patients after renal transplantation (ISAR-denerve). 2015 , 30, 1928-36	12
1309	Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease. 2015 , 87, 116-27	22
1308	Intrarenal bradykinin elicits reno-renal reflex sympatho-excitation and renal nerve-dependent fluid retention. 2015 , 213, 731-9	20
1307	Renal sympathetic nerves - what have they got to do with cardiovascular disease?. 2015 , 100, 359-65	11
1306	Resistant hypertension: what the cardiologist needs to know. 2015 , 36, 2686-95	30
1305	Distal and Tributary Targets: A New Branching Point for Renal Denervation?. 2015 , 66, 1776-1778	3
1304	Physiology of the Renal Interstitium. 2015 , 10, 1831-40	60
1303	Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. 2015 , 58, 2885-98	43
1302	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. 2015 , 104, 1097-105	61
1301	Effects of Renal Sympathetic Denervation on Arterial Stiffness and Blood Pressure Control in Resistant Hypertensive Patients: A Single Centre Prospective Study. 2015 , 22, 411-6	9
1300	Blood pressure target goals from guidelines of 2002-2014. 2015 , 11, 247-50	
1299	The double challenge of resistant hypertension and chronic kidney disease. 2015 , 386, 1588-98	108
1298	If you lose your nerves, at least you will not get kidney fibrosis!. 2015 , 87, 275-7	1

1297	[Renal denervation in refractory hypertension: joint statement of the German hypertension league DHL eV and the German societies of cardiology, angiology, nephrology and radiology]. 2015 , 140, 363	1
1296	Multimodality Intra-Arterial Imaging Assessment of the Vascular Trauma Induced by Balloon-Based and Nonballoon-Based Renal Denervation Systems. 2015 , 8, e002474	16
1295	Fundamentals of Clinical Trials. 2015 ,	128
1294	Hepatic denervation and dyslipidemia in obese Zucker (fa/fa) rats. 2015 , 39, 1655-8	13
1293	Catheter-based Renal Artery Denervation for Resistant Hypertension: Promise Unfulfilled or Unsettled?. 2015 , 17, 56	1
1292	Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. 2015 , 36, 2219-27	137
1291	Predictors as well as surrogate and hard endpoints in cardiovascular disease. 2015 , 36, 2197-9	4
1290	Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension. 2015 , 101, 10-6	32
1289	Sympathetic and Renin-Angiotensin Activity in the Pathophysiology of Hypertension. 2015 , 723-749	
1288	[Resistant hypertension and carotid baroreceptors stimulation]. 2015 , 44, 730-6	0
1287	Hypertension and chronic kidney disease. 2015 , 61, 387-95	28
1286	[Management of arterial hypertension]. 2015 , 40, 929-40; quiz 941-2	0
1285	Autonomic Dysregulation as a Therapeutic Target for Acute HF. 2015 , 17, 403	3
1284	Adherence to antihypertensive medications: is prescribing the right pill enough?. 2015 , 30, 1649-56	23
1283	Safety and performance of the next generation EnligHTN renal denervation system in patients with drug-resistant, uncontrolled hypertension: The EnligHTN III first-in-human multicentre study. 2015 , 8, 4-10	2
1282	Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials. 2015 , 66, 2536-49	35
1281	The Reply. 2015 , 128, e27-8	4
1280	Renal denervation for the treatment of hypertension: If at first you don't succeed, try and try again. 2015 , 67, 192-3	

1279	Autonomic Modulation in Heart Failure: Ready for Prime Time?. 2015 , 17, 103	5
1278	Renal denervation for resistant hypertension. 2015 , 386, 1239-1240	2
1277	Renal denervation for resistant hypertension - Authors' reply. 2015 , 386, 1240	1
1276	Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTN I first-in-human study using a multi-electrode ablation system. 2015 , 201, 345-50	28
1275	Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. 2015 , 65, 193-9	84
1274	Cardiac contractility modulation: the next cardiac resynchronization therapy or another renal sympathetic denervation?. 2015 , 21, 24-6	2
1273	Renal nerve stimulation to predict responders to renal denervation. 2015 , 29, 281-2	1
1272	Renal sympathetic denervation: a 'remote control' for atrial fibrillation therapy. 2015 , 17, 509-10	2
1271	Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. 2015 , 12, e5-e29	64
1270	Individual-patient visit-by-visit office and ambulatory blood pressure measurements over 24months in patients undergoing renal denervation for hypertension. 2015 , 181, 96-101	3
1269	Renal denervation: simply trapped by complexity?. 2015 , 36, 199-202	49
1268	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. 2015 , 36, 219-27	349
1267	Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. 2015 , 65, 407-13	150
1266	Resistant hypertension: four years of follow-up of an unusual course after renal denervation in a patient with end stage renal disease. 2015 , 180, 86-7	
1265	Effects of renal denervation on end organ damage in hypertensive patients. 2015 , 22, 558-67	18
1264	Resistant hypertension: medical management and alternative therapies. 2015 , 33, 75-87	7
1263	A novel method of selective ablation of afferent renal nerves by periaxonal application of capsaicin. 2015 , 308, R112-22	69
1262	Renal nerve ablation. 2015 , 101, 320-8	4

1261	Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study. 2015 , 29, 292-5	52
1260	Cardio-Renal Clinical Challenges. 2015 ,	1
1259	Renal Denervation. 2015 ,	2
1258	The discovery of hypertension: evolving views on the role of the kidneys, and current hot topics. 2015 , 308, F167-78	31
1257	Pathogenesis of obstructive sleep apnoea in hypertensive patients: role of fluid retention and nocturnal rostral fluid shift. 2015 , 29, 342-50	26
1256	Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension. 2015 , 104, 175-84	33
1255	Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. 2015 , 65, 393-400	105
1254	Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. 2015 , 36, 425-33	208
1253	Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. 2015 , 28, 355-61	109
1252	2013 ESH/ESC guidelines for the management of arterial hypertension: what has changed in daily clinical practice?. 2015 , 22, 43-53	13
1251	Emerging Therapies for Chronic Kidney Disease. 2015 , 771-780	
1250	Renal denervation for treatment of cardiac arrhythmias: state of the art and future directions. 2015 , 26, 233-8	14
1249	Treating hypertension and prehypertension in older people: when, whom and how. 2015 , 80, 31-6	9
1248	Current Approaches to Treatment of Ventricular Arrhythmias in Patients with Coronary Artery Disease. 2016 , 141-152	
1247	Systemic Hemodynamic Atherothrombotic Syndrome and Resonance Hypothesis of Blood Pressure Variability: Triggering Cardiovascular Events. 2016 , 46, 456-67	20
1246	Long-Term Effects of Renal Denervation on Blood Pressure Burden in Patients with Resistant Arterial Hypertension. 2016 , 08,	
1245	Kidneys: The Victim Of Hypertension: Review. 2016 , 06,	
1244	Long-term quality of life and clinical outcomes in patients with resistant hypertension treated with renal denervation. 2016 , 12, 329-333	3

1243	Favorable effects on arterial stiffness after renal sympathetic denervation for the treatment of resistant hypertension: a cardiovascular magnetic resonance study. 2016 , Volume 4, 45-51	
1242	Bilateral Renal Denervation Ameliorates Isoproterenol-Induced Heart Failure through Downregulation of the Brain Renin-Angiotensin System and Inflammation in Rat. 2016 , 2016, 3562634	7
1241	Guideline for the diagnosis and management of hypertension in adults - 2016. 2016 , 205, 85-9	155
1240	Hypertension: Implications of Current JNC 8 Guidelines on Treatment. 2016 , 30-49	
1239	Impact of Renal Sympathetic Denervation on Left Ventricular Structure and Function at 1-Year Follow-Up. 2016 , 11, e0149855	19
1238	Effects of Renal Denervation Documented in the Austrian National Multicentre Renal Denervation Registry. 2016 , 11, e0161250	12
1237	Renal Denervation in a Real Life Setting: A Gradual Decrease in Home Blood Pressure. 2016 , 11, e0162251	2
1236	Chronic Kidney Disease As a Potential Indication for Renal Denervation. 2016 , 7, 220	6
1235	Whey Proteins and Their Value-Added Applications. 2016 , 303-313	2
1234	The Skeletal Muscle Microvasculature and Its Effects on Metabolism. 2016 ,	0
1233	Device-Based Therapy for Drug-Resistant Hypertension: An Update. 2016 , 18, 64	8
1232	Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. 2016 , 34, 1639-47	68
1231	Blood Pressure Responses to Endovascular Stimulation: A Potential Therapy for Autonomic Disorders With Vasodilatation. 2016 , 27, 1078-85	2
1230	Long-term verification of functional and structural renal damage after renal sympathetic denervation. 2016 , 87, 1298-303	3
1229	Quantifying the 3 Biases That Lead to Unintentional Overestimation of the Blood Pressure-Lowering Effect of Renal Denervation. 2016 , 9, 14-22	26
1228	Predictors of response to renal denervation for resistant arterial hypertension: a single center experience. 2016 , 34, 123-9	13
1227	Device-based Therapy for Hypertension. 2016 , 18, 61	27
1226	Eminence, common sense, and evidence: a comment to the Andreas Grützlig lecture 2015. 2016 , 37, 2020-2	1

1225	Baroreflex activation therapy in patients with prior renal denervation. 2016 , 34, 1630-8	15
1224	Translational neurocardiology: preclinical models and cardioneural integrative aspects. 2016 , 594, 3877-909	89
1223	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension: 12-month outcomes from the global SYMPPLICITY registry. 2016 , 34, 2480-2486	17
1222	Management der arteriellen Hypertonie. 2016 , 13, 49-57	
1221	Renal Denervation for Resistant Hypertension. 2016 , 499-506	
1220	Impacts of Surgically Performed Renal Denervation on the Cardiovascular and Electrophysiological Variables in the Chronic Atrioventricular Block Dogs - Comparison With Those of Amiodarone Treatment. 2016 , 80, 1556-63	4
1219	Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. 2016 , 30, 368-73	30
1218	Renal Denervation Improves the Baroreflex and GABA System in Chronic Kidney Disease-induced Hypertension. 2016 , 6, 38447	17
1217	What we need to know about renal nerve ablation for treatment of hypertension and other states of sympathetic overactivity. 2016 , 311, F1267-F1270	7
1216	Pathogenesis of Macrovascular Complications in Diabetes. 2016 , 599-628	1
1215	Prevalence and characteristics of patients with resistant hypertension and chronic kidney disease. 2016 , 36, 523-529	4
1214	Renal Artery Vasodilation May Be An Indicator of Successful Sympathetic Nerve Damage During Renal Denervation Procedure. 2016 , 6, 37218	10
1213	Spirolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. 2016 , 34, 1863-71	50
1212	Spirolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension. 2016 , 34, 1701-3	2
1211	The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. 2016 , 34, 2475-2479	7
1210	Executive summary of the joint position paper on renal denervation of the Cardiovascular and Interventional Radiological Society of Europe and the European Society of Hypertension. 2016 , 34, 2303-2304	3
1209	Aggressive renal sympathetic denervation approach to treating resistant hypertension: A fresh start?. 2016 , 16, 42	
1208	Renal disease pathophysiology and treatment: contributions from the rat. 2016 , 9, 1419-1433	30

1207	Renal denervation in the treatment of resistant hypertension: Dead, alive or surviving?. 2016 , 35, 531-538	
1206	Editorial: Can Renal Denervation Work? Yes, But First One Must Denervate. Lessons from Human Renal Sympathetic Nerve Anatomy. 2016 , 29, 601-602	1
1205	Renal denervation for resistant hypertension: no. 2016 , 11, 495-8	0
1204	Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials. 2016 , 13, 1748-54	16
1203	Renal denervation for human hypertension: is there a future?. 2016 , 10, 390-2	
1202	Trattamento endovascolare delle lesioni delle arterie renali. 2016 , 21, 1-8	
1201	Long-term follow-up after radio-frequency catheter-based denervation in patients with resistant hypertension. 2016 , 215, 472-5	
1200	Update in Hypertension Therapy. 2016 , 100, 665-93	6
1199	Emerging concepts for patients with treatment-resistant hypertension. 2016 , 26, 700-706	9
1198	Long-term follow-up of renal arteries after radio-frequency catheter-based denervation using optical coherence tomography and angiography. 2016 , 32, 855-62	5
1197	Resistant Hypertension: An Incurable Disease or Just a Challenge For Our Medical Skill?. 2016 , 23, 347-353	1
1196	[Prevalence of true resistant hypertension among uncontrolled hypertensive patients referred to a tertiary health care center]. 2016 , 65, 191-6	2
1195	Non-invasive Renal Denervation: Update on External Ultrasound Approaches. 2016 , 18, 48	6
1194	A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. 2016 , 10, 510-516.e1	10
1193	The effect of renal denervation on resistant hypertension: Meta-analysis of randomized controlled clinical trials. 2016 , 38, 278-86	8
1192	Neural modulation for hypertension and heart failure. 2016 , 214, 320-30	14
1191	Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison. 2016 , 18, 36	14
1190	New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension. 2016 , 18, 34	22

1189	Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated 'Anticipation Medicine' for Zero Cardiovascular Event. 2016 , 59, 262-281	88
1188	Hypertension: a problem of organ blood flow supply-demand mismatch. 2016 , 12, 339-49	13
1187	Electrical stimulation-based evaluation for functional modification of renal autonomic nerve activities induced by catheter ablation. 2016 , 13, 1707-15	10
1186	Persistent Increase in Blood Pressure After Renal Nerve Stimulation in Accessory Renal Arteries After Sympathetic Renal Denervation. 2016 , 67, 1211-7	31
1185	Residual Sympathetic Responsiveness After Catheter-Based Renal Denervation: Lessons From Renal Nerve Stimulation. 2016 , 67, 1117-8	3
1184	The future for renal denervation depends on embracing the lessons learned from our previous studies. 2016 , 10, 396-8	
1183	New strategies to tackle diabetic kidney disease. 2016 , 25, 348-54	2
1182	Renal denervation in hypertensive patients not on blood pressure lowering drugs. 2016 , 105, 755-62	17
1181	[Pulmonary (Arterial) Hypertension]. 2016 , 70, 630-637	3
1180	Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. 2016 , 134, 847-57	98
1179	Cardiac sympatho-vagal balance and ventricular arrhythmia. 2016 , 199, 29-37	44
1178	The Primary Outcome Is Positive - Is That Good Enough?. <i>New England Journal of Medicine</i> , 2016 , 375, 971-9	59.2 78
1177	Research update for articles published in EJCI in 2014. 2016 , 46, 880-94	
1176	Renal Nerve Stimulation-Induced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation. 2016 , 68, 707-14	58
1175	Renal Sympathetic Hyperactivity in Hypertension: True or False?. 2016 , 119, e33-4	2
1174	Renal denervation in challenging anatomy: Current strategies and pre-procedural imaging. 2016 , 224, 1-3	
1173	A Perspective on the Delivery of Renal Denervation Therapy Based on Pre-Clinical Data. 2016 , 1, 288-295	
1172	"Won't Get Fooled Again". 2016 , 9, 1300-1301	1

- 1171 Reply: Chemical Renal Denervation Revisited. **2016**, 9, 1307-1308
- 1170 Dissection anatomique assistée par ordinateur (DAAO) du plexus rénal pour affiner la dénervation rénale dans le traitement de l'hypertension artérielle résistante. **2016**, 100, 135
- 1169 ISN Forefronts Symposium 2015: The Evolution of Hypertension-Old Genes, New Concepts. **2016**, 1, 197-203 4
- 1168 Leptin as a Mediator of Obesity-Induced Hypertension. **2016**, 5, 397-404 69
- 1167 A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. **2016**, 388, 2665-2712 413
- 1166 Executive Summary of the Joint Position Paper on Renal Denervation of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and the European Society of Hypertension (ESH). **2016**, 39, 1681-1683 1
- 1165 Renal sympathetic denervation for treatment of patients with atrial fibrillation: Reappraisal of the available evidence. **2016**, 13, 2388-2394 16
- 1164 Anatomic Patterns of Renal Arterial Sympathetic Innervation: New Aspects for Renal Denervation. **2016**, 29, 594-600 14
- 1163 Renal Denervation: A Historical Perspective. **2016**, 201-213
- 1162 Modern Challenges in Treating Hypertension. **2016**, 38, 2132-2134 0
- 1161 [PATHWAY-2 study. Vision of the family physician in the approach of resistant hypertension]. **2016**, 33, 145-149
- 1160 Renal denervation in the treatment of resistant hypertension: Dead, alive or surviving?. **2016**, 35, 531-8 1
- 1159 Scientists of Tomorrow at the Frontiers of Cardiovascular Biology 2016 in Florence: translating basic science into clinical practice is the next frontier. **2016**, 111, 120-2 3
- 1158 Resting Afferent Renal Nerve Discharge and Renal Inflammation: Elucidating the Role of Afferent and Efferent Renal Nerves in Deoxycorticosterone Acetate Salt Hypertension. **2016**, 68, 1415-1423 66
- 1157 Splitting atoms: the Endocrine Society guideline for the management of primary aldosteronism. **2016**, 4, 805-7 5
- 1156 Prevalence and characteristics of patients with resistant hypertension and chronic kidney disease. **2016**, 36, 523-529 7
- 1155 Accessory renal arteries: Prevalence in resistant hypertension and an important role in nonresponse to radiofrequency renal denervation. **2016**, 17, 470-473 8
- 1154 Renal Denervation Reverses Hepatic Insulin Resistance Induced by High-Fat Diet. **2016**, 65, 3453-3463 16

1153	Renal Denervation: Past, Present, and Future. 2016 , 1, 253-263		
1152	Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. 2016 , 18, 160-8		58
1151	Renal Denervation vs Pharmacotherapy for Resistant Hypertension: A Meta-Analysis. 2016 , 18, 733-40		8
1150	Catheter-Based Renal Denervation Reduces Hypoxia-Triggered Nocturnal Blood Pressure Peak in Obstructive Sleep Apnea Syndrome. 2016 , 18, 707-9		20
1149	Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Apparent Treatment-Resistant Hypertension. 2016 , 18, 817-24		15
1148	Endovascular Interventional Cardiology: 2015 in Review. 2016 , 29, 5-10		2
1147	Predictors of blood pressure response: Obesity is associated with a less pronounced treatment response after renal denervation. 2016 , 87, E30-8		9
1146	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. 2017 , 38, 93-100		79
1145	American Society of Hypertension Scientific Statements Addressing Resistant Hypertension. 2016 , 18, 175-8		2
1144	Management of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm. 2016 , 18, 129-38		14
1143	Does Renal Denervation Fit All Resistant Hypertension? The Role of Genetics. 2016 , 18, 161-2		1
1142	Raising the Bar in Renal Sympathetic Denervation Research and Reporting. 2016 , 18, 89-94		2
1141	Renal Denervation in Patients With Uncontrolled Hypertension and Confirmed Adherence to Antihypertensive Medications. 2016 , 18, 565-71		7
1140	Controversies Surrounding Renal Denervation: Lessons Learned From Real-World Experience in Two United Kingdom Centers. 2016 , 18, 585-92		5
1139	The Primary Outcome Fails - What Next?. <i>New England Journal of Medicine</i> , 2016 , 375, 861-70	59.2	152
1138	Renal Nerve Denervation, Adherence, and Management of Resistant Hypertension. 2016 , 134, 858-60		6
1137	Infiltration of the sphenopalatine ganglion decreases blood pressure in newly diagnosed and never treated patients with essential hypertension. 2016 , 223, 345-351		5
1136	Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. 2016 , 105, 873-9		55

1135	[Invasive treatment of hypertension : Update 2016]. 2016 , 57, 871-8	1
1134	Interventional Therapies for Secondary and Essential Hypertension. 2016 ,	
1133	Primary Aldosteronism: A Field on the Move. 2016 , 29-55	1
1132	Hypertension in Chronic Kidney Disease. 2017 , 956, 307-325	51
1131	Resistant Hypertension: Is the Number of Drugs a Reliable Marker of Resistance?. 2016 , 68, 1346-1348	1
1130	Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPPLICITY HTN-3 Trial. 2016 , 80, 1404-12	41
1129	Deregulation of Soluble Adhesion Molecules in Resistant Hypertension and Its Role in Cardiovascular Remodeling. 2016 , 80, 1196-201	12
1128	Encouraging Results of Renal Denervation in Resistant Hypertension Patients With Obstructive Sleep Apnea. 2016 , 80, 1316-8	
1127	Importance of Out-of-Clinic Blood Pressure Measurement for Device-Based Hypertensive Therapy. 2016 , 80, 1898-900	
1126	Troponin and the J-Curve of Diastolic Blood Pressure: When Lower Is Not Better. 2016 , 68, 1723-1726	26
1125	Anatomical and procedural determinants of catheter-based renal denervation. 2016 , 17, 474-479	12
1124	Unilateral Carotid Body Resection in Resistant Hypertension: An Exciting First Step Toward a New Therapy?. 2016 , 1, 325-327	1
1123	Prevalence of treatment-resistant hypertension and important associated factors-results from the Swedish Primary Care Cardiovascular Database. 2016 , 10, 838-846	12
1122	Current Status of Renal Denervation in Hypertension. 2016 , 18, 107	3
1121	Ruminations About Renal Denervation. 2016 , 134, 267-9	2
1120	Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension. 2016 , 10, 841-51	1
1119	Interventional procedures and future drug therapy for hypertension. 2017 , 38, 1101-1111	26
1118	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I). 2016 , 9,	37

1117	Bradykinin receptor blockade restores the baroreflex control of renal sympathetic nerve activity in cisplatin-induced renal failure rats. 2016 , 218, 212-224	8
1116	Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"?. 2017 , 30, 841-846	3
1115	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. 2016 , 134, e535-e578	164
1114	Resistant Hypertension. 2017 , 956, 181-189	1
1113	Anti-Inflammatory Effects and Prediction of Blood Pressure Response by Baseline Inflammatory State in Catheter-Based Renal Denervation. 2016 , 18, 1173-1179	6
1112	Early pre-occlusive bilateral renal artery stenosis after renal denervation. 2016 , 225, 96-98	0
1111	Second denervation in a patient with resistant hypertension. 2016 , 105, 880-3	1
1110	Device Therapies for Resistant Hypertension. 2016 , 38, 2152-2158	4
1109	Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. 2016 , 68, 2016-2025	36
1108	Renal Denervation for Resistant Hypertension. 2016 , 59, 295-302	2
1107	Minoxidil for Treatment of Resistant Hypertension in Chronic Kidney Disease--A Retrospective Cohort Analysis. 2016 , 18, 1162-1167	7
1106	Renal Denervation. 2017 , 956, 261-277	
1105	Renal Afferents. 2016 , 18, 69	13
1104	A cholinergic-sympathetic pathway primes immunity in hypertension and mediates brain-to-spleen communication. 2016 , 7, 13035	73
1103	Hypertension in the Dialysis Patient. 2016 , 133-166	
1102	Prolonged Baroreflex Activation Abolishes Salt-Induced Hypertension After Reductions in Kidney Mass. 2016 , 68, 1400-1406	10
1101	Retrospective morphometric study of the suitability of renal arteries for renal denervation according to the Symplicity HTN2 trial criteria. 2016 , 6, e009351	4
1100	Response by Grassi et al to Letter Regarding Article, "The Sympathetic Nervous System Alterations in Human Hypertension". 2016 , 119, e35-6	1

1099	Complex reinnervation pattern after unilateral renal denervation in rats. 2016 , 310, R806-18	20
1098	Renal Sympathetic Denervation: Hibernation or Resurrection?. 2016 , 135, 87-97	5
1097	Hypertension control and care at Mulago Hospital ambulatory clinic, Kampala-Uganda. 2016 , 9, 487	9
1096	Diabetes und Hypertonie. 2016 , 12, 312-318	
1095	Renal denervation: are we at a crossroads?. 2016 , 24, 447-8	0
1094	Renal denervation for uncontrolled hypertension: critical review of the evidence. 2017 , 26, 114-122	5
1093	Renal denervation for resistant hypertension: closing in on potential confounders. 2016 , 34, 1505-6	1
1092	Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. 2016 , 34, 1854-62	16
1091	The effect of two different renal denervation strategies on blood pressure in resistant hypertension: Comparison of full-length versus proximal renal artery ablation. 2016 , 88, 786-795	4
1090	Physiology Unmasks Hypertension. 2016 , 68, 252-6	1
1089	The impact of renal sympathetic denervation on cardiac electrophysiology and arrhythmias: A systematic review of the literature. 2016 , 220, 87-101	6
1088	Renal denervation in the era of HTN-3. Comprehensive review and glimpse into the future. 2016 , 10, 656-70	12
1087	Modulation of the sympathetic nervous system by renal denervation prevents reduction of aortic distensibility in atherosclerosis prone ApoE-deficient rats. 2016 , 14, 167	10
1086	Radiofrequency Renal Denervation Protects the Ischemic Heart via Inhibition of GRK2 and Increased Nitric Oxide Signaling. 2016 , 119, 470-80	29
1085	Tratamiento endovascular de las lesiones de las arterias renales. 2016 , 16, 1-8	
1084	Renal Sympathetic Denervation by CT-Guided Ethanol Injection: A Phase II Pilot Trial of a Novel Technique. 2016 , 39, 251-60	7
1083	Random Guess and Wishful Thinking are the Best Blinding Scenarios. 2016 , 3, 117-121	18
1082	Resistance to renal denervation therapy - Identification of underlying mechanisms by analysis of differential DNA methylation. 2016 , 11, 80-86	

1081	Future prospects for renal artery denervation. 2016 , 10, 393-5	1
1080	Renal nerves dynamically regulate renal blood flow in conscious, healthy rabbits. 2016 , 310, R156-66	4
1079	Renal sympathetic denervation using MR-guided high-intensity focused ultrasound in a porcine model. 2016 , 4, 3	6
1078	Hypertensie die slecht op behandeling reageert. 2016 , 59, 24-26	
1077	Renal denervation with standard radiofrequency ablation catheter is effective in 24-hour ambulatory blood pressure reduction - follow-up at 1/3/6/12 months. 2016 , 24, 449-55	2
1076	Interventionelle Verfahren bei therapieresistenter Hypertonie. 2016 , 16, 56-64	
1075	Use of Biomarkers in the Evaluation and Treatment of Hypertensive Patients. 2016 , 18, 54	8
1074	Renal Denervation: a Field in Flux. 2016 , 18, 56	2
1073	Renal denervation in patients with heart failure with preserved ejection fraction: end of the beginning?. 2016 , 18, 713-5	2
1072	Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. 2016 , 594, 3911-54	131
1071	Endpoint design for future renal denervation trials - Novel implications for a new definition of treatment response to renal denervation. 2016 , 220, 273-8	3
1070	Is renal denervation an effective treatment for hypertension? Comparison of recent meta-analysis and a multinational registry. 2016 , 21, 128-30	1
1069	Management of resistant hypertension: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology. 2016 , 30, 657-663	10
1068	Blood Pressure: Return of the Sympathetics?. 2016 , 18, 7	7
1067	Synthesis and fluorescent study of 5-phenyl furocoumarin derivatives as vasodilatory agents. 2016 , 26, 640-644	9
1066	Closed-Loop Neuromodulation Technology for Baroreflex Blood Pressure Control. 2016 , 104, 432-443	4
1065	The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease. 2016 , 21, 344-52	15
1064	Hypertension in 2015: Resistant hypertension: impact and evolving treatment options. 2016 , 12, 70-2	3

1063	Renal denervation mitigates cardiac remodeling and renal damage in Dahl rats: a comparison with β receptor blockade. 2016 , 39, 217-26	21
1062	The morphological substrate for Renal Denervation: Nerve distribution patterns and parasympathetic nerves. A post-mortem histological study. 2016 , 204, 71-9	29
1061	The effects of renal denervation on resistant hypertension patients: a meta-analysis. 2016 , 21, 206-14	4
1060	Renal denervation for resistant hypertension: yes. 2016 , 11, 491-3	
1059	Recent Developments and Controversies in the Treatment of Resistant Hypertension. 2016 , 124, 178-86	1
1058	Transcatheter Alcohol-Mediated Perivascular Renal Denervation With the Peregrine System: First-in-Human Experience. 2016 , 9, 589-98	35
1057	Effect of Renal Sympathetic Denervation on Specific MicroRNAs as an Indicator of Reverse Remodeling Processes in Hypertensive Heart Disease. 2016 , 18, 497-502	4
1056	Laparoscopic Renal Denervation for Uncontrolled Hypertension Due to Medication Intolerance: A Case Report. 2016 , 68, 131-3	5
1055	Long-Term Effects of Renal Sympathetic Denervation on Hypertensive Patients With Mild to Moderate Chronic Kidney Disease. 2016 , 18, 190-6	32
1054	Renal Denervation for the Hypertension of Chronic Kidney Disease: A Special Case?. 2016 , 18, 187-9	1
1053	Chemical Renal Denervation: The Pursuit for Simplicity. 2016 , 9, 599-601	
1052	Long-term effects of multielectrode renal denervation on cardiac adaptations in resistant hypertensive patients with left ventricular hypertrophy. 2016 , 30, 714-719	6
1051	Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. 2016 , 10, 307-17	20
1050	Reductions of left ventricular mass and atrial size following renal denervation: a meta-analysis. 2016 , 105, 648-656	20
1049	The nervous heart. 2016 , 120, 199-209	36
1048	The need for and the challenges of measuring renal sympathetic nerve activity. 2016 , 13, 1166-1171	4
1047	The rise, fall, and possible resurrection of renal denervation. 2016 , 13, 238-44	28
1046	Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. 2016 , 105, 592-600	10

1045	Renal artery sympathetic denervation: observations from the UK experience. 2016 , 105, 544-52	26
1044	Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016. 2016 , 129, 661-6	24
1043	Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension. 2016 , 67, 701-9	46
1042	Safety and Feasibility of Renal Sympathetic Denervation in Patients With Insufficient Renal Artery Length. 2016 , 50, 63-7	0
1041	Evidence for a critical role of the sympathetic nervous system in hypertension. 2016 , 10, 457-66	102
1040	Highlights of the 2015 ERA-EDTA congress: chronic kidney disease, hypertension. 2016 , 31, 1044-6	6
1039	Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?. 2016 , 18, 25	6
1038	A Woman With Treatment-Resistant Hypertension. 2016 , 67, 243-50	2
1037	Hemodynamic and neural responses to renal denervation of the nerve to the clipped kidney by cryoablation in two-kidney, one-clip hypertensive rats. 2016 , 310, R197-208	12
1036	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study. 2016 , 67, 397-403	60
1035	Resistant Hypertension: Mineralocorticoid Receptor Antagonist or Renal Denervation?. 2016 , 67, 278-80	6
1034	Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. 2016 , 105, 364-71	42
1033	Renal sympathetic denervation suppresses atrial fibrillation induced by acute atrial ischemia/infarction through inhibition of cardiac sympathetic activity. 2016 , 203, 187-95	21
1032	Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). 2016 , 30, 315-21	15
1031	Renal Denervation: A Novel Therapy at the Crossroads of Imaging, Intervention, and Innovation. 2016 , 21, 312-6	2
1030	A Novel Swine Model of Spontaneous Hypertension With Sympathetic Hyperactivity Responds Well to Renal Denervation. 2016 , 29, 63-72	11
1029	Novel mechanisms in the pathogenesis of atrial fibrillation: practical applications. 2016 , 37, 1573-81	71
1028	A perspective on sympathetic renal denervation in chronic congestive heart failure. 2016 , 21, 1-10	6

1027	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. 2016 , 171, 82-91	104
1026	The effect of renal sympathetic denervation on nocturnal dipping in patients with resistant hypertension; observational data from a tertiary referral centre in the Republic of Ireland. 2016 , 185, 635-641	4
1025	Defined daily dose (DDD) and its potential use in clinical trials of resistant hypertension. 2016 , 202, 515-6	10
1024	Effects of renal sympathetic denervation on cardiac sympathetic activity and function in patients with therapy resistant hypertension. 2016 , 202, 609-14	10
1023	Mid-Term Vascular Safety of Renal Denervation Assessed by Follow-up MR Imaging. 2016 , 39, 426-32	8
1022	Plasma renalase concentration before and after radiofrequency renal denervation in patients with resistant hypertension. 2016 , 30, 410-1	1
1021	Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. 2016 , 30, 191-6	13
1020	What Is Happening in the Area of Device-Based Blood Pressure Treatment?. 2016 , 18, 247	
1019	Renal sympathetic denervation in uncontrolled arterial hypertension after successful repair for aortic coarctation. 2016 , 202, 322-7	1
1018	Renal artery anatomy affects the blood pressure response to renal denervation in patients with resistant hypertension. 2016 , 202, 388-93	14
1017	Neuromodulation for cardiac arrhythmia. 2016 , 13, 584-92	43
1016	Renal sympathetic denervation: effect on ambulatory blood pressure and blood pressure variability in patients with treatment-resistant hypertension. The ReShape CV-risk study. 2016 , 30, 153-7	12
1015	Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. 2016 , 30, 83-9	48
1014	Trained breathing-induced oxygenation acutely reverses cardiovascular autonomic dysfunction in patients with type 2 diabetes and renal disease. 2016 , 53, 217-26	9
1013	Preliminary effects of renal denervation with saline irrigated catheter on cardiac systolic function in patients with heart failure: A Prospective, Randomized, Controlled, Pilot Study. 2017 , 89, E153-E161	28
1012	Sympathetic innervation of the kidney in health and disease: Emphasis on the role of purinergic cotransmission. 2017 , 204, 4-16	14
1011	Interventional therapy for hypertension: Back on track again?. 2017 , 54, 18-25	
1010	Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach. 2017 , 22, 225-231	3

1009	Present and Future of Interventional Treatment of Resistant Hypertension. 2017 , 19, 4	5
1008	Arterial (Aortic) Stiffness in Patients with Resistant Hypertension: from Assessment to Treatment. 2017 , 19, 2	20
1007	Effects of renal sympathetic denervation on blood pressure, sleep apnoea severity and metabolic indices: a prospective cohort study. 2017 , 30, 180-184	10
1006	Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension). 2017 , 69, 494-500	19
1005	If in doubt, cut it out: the role of surgery in primary hypertension. 2017 , 595, 2419-2420	
1004	Cardioversion for Atrial Fibrillation Improves Quality of Life: It's Obvious (or Isn't It?). 2017 , 33, 425-427	0
1003	True Resistant Hypertension Following Observed Drug Ingestion: A Systematic Evaluation. 2017 , 19, 250-255	11
1002	Renal denervation for resistant hypertension. 2017 , 2, CD011499	17
1001	Catheter-Based Renal Denervation Exacerbates Blood Pressure Fall During Hemorrhage. 2017 , 69, 951-964	28
1000	Effects of percutaneous renal sympathetic denervation on cardiac function and exercise tolerance in patients with chronic heart failure. 2017 , 36, 45-51	9
999	Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. 2017 , 69, 678-684	48
998	Renal sympathetic denervation for treatment of patients with heart failure: summary of the available evidence. 2017 , 49, 384-395	7
997	Pathophysiology and Potential Non-Pharmacologic Treatments of Obesity or Kidney Disease Associated Refractory Hypertension. 2017 , 19, 18	5
996	The innervation of the kidney in renal injury and inflammation: a cause and consequence of deranged cardiovascular control. 2017 , 220, 404-416	10
995	Are Important Components of Kidney Function Lost With Renal Denervation?. 2017 , 69, 965-967	
994	Renal Sympathetic Denervation System via Intraluminal Ultrasonic Ablation: Therapeutic Intravascular Ultrasound Design and Preclinical Evaluation. 2017 , 28, 740-748	4
993	Effects of Renal Artery Denervation on Ventricular Arrhythmias in a Postinfarct Model. 2017 , 10, e004172	21
992	Postinfarct Ventricular Arrhythmias: Should We Calm the Renal Nerves?. 2017 , 10, e004995	

991	Beneficial Effect of Renal Denervation on Ventricular Premature Complex Induced Cardiomyopathy. 2017 , 6,	14
990	Renal Denervation Therapy for the Treatment of Arrhythmias: Is the Sky the Limit?. 2017 , 6,	3
989	Neuromodulation for systolic heart failure: more than a placebo effect?. 2017 , 19, 401-403	
988	Multidisciplinary Approach in the Treatment of Resistant Hypertension. 2017 , 19, 9	7
987	Device-Directed Therapy for Resistant Hypertension. 2017 , 35, 255-260	2
986	Significant correlation between renal I-metaiodobenzylguanidine scintigraphy and muscle sympathetic nerve activity in patients with primary hypertension. 2017 , 24, 363-371	4
985	A heart-brain-kidney network controls adaptation to cardiac stress through tissue macrophage activation. 2017 , 23, 611-622	78
984	Hypertension in the Kidney Transplant Recipient: Overview of Pathogenesis, Clinical Assessment, and Treatment. 2017 , 25, 102-109	11
983	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. 2017 , 35, 1093-1099	19
982	Renal denervation in less severe forms of (resistant) hypertension-Quo vadis?. 2017 , 19, 369-370	1
981	Renal denervation beyond the bifurcation: The effect of distal ablation placement on safety and blood pressure. 2017 , 19, 371-378	7
980	Long-Term Follow-Up of Baroreflex Activation Therapy in Resistant Hypertension: Another Piece of the Puzzle?. 2017 , 69, 782-784	2
979	Redo renal denervation using a multi-electrode radiofrequency system in patients with persistent therapy-resistant hypertension. 2017 , 25, 359-364	0
978	Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. 2017 , 26, 321-331	17
977	Carotid Body Denervation Markedly Improves Survival in Rats With Hypertensive Heart Failure. 2017 , 30, 791-798	8
976	Effect of catheter-based renal denervation on left ventricular function, mass and (un)twist with two-dimensional speckle tracking echocardiography. 2017 , 15, 158-165	2
975	Resistant Hypertension: An Update of Experimental and Clinical Findings. 2017 , 70, 5-9	30
974	Resistant hypertension in 2017. 2017 , 32, 389-396	5

973	Safety and performance of the second generation EnligHTN [®] Renal Denervation System in patients with drug-resistant, uncontrolled hypertension. 2017 , 262, 94-100	23
972	Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. 2017 , 38, 3272-3281	70
971	Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome. 2017 , 35, 1100-1108	17
970	Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis. 2017 , 35, 1750-1757	8
969	Ultrasound-based renal sympathetic denervation for the treatment of therapy-resistant hypertension: a single-center experience. 2017 , 35, 1310-1317	14
968	Treatment of Ventricular Arrhythmias and Use of Implantable Cardioverter-Defibrillators to Improve Survival in Older Adult Patients with Cardiac Disease. 2017 , 13, 589-605	2
967	Therapeutic value of renal denervation in cardiovascular disease?. 2017 , 220, 11-13	8
966	Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. 2017 , 26, 195-203	21
965	Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. 2017 , 19, 39	5
964	Renal denervation decreases blood pressure and renal tyrosine hydroxylase but does not augment the effect of hypotensive drugs. 2017 , 39, 290-294	5
963	Recognition and Management of Resistant Hypertension. 2017 , 12, 524-535	34
962	Aerobic versus isometric handgrip exercise in hypertension: a randomized controlled trial. 2017 , 35, 2199-2206	24
961	Device-Based Approaches for the Treatment of Arterial Hypertension. 2017 , 19, 59	11
960	Cartoon. 2017 , 28, 748	0
959	Letter to the Editor. 2017 , 39, 388	
958	Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPPLICITY Registry. 2017 , 35, 148-153	15
957	Denervation of the distal renal arterial branches vs. conventional main renal artery treatment: a randomized controlled trial for treatment of resistant hypertension. 2017 , 35, 369-375	38
956	Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPPLICITY Registry. 2017 , 19, 833-839	9

955	Improving public health by improving clinical trial guidelines and their application. 2017 , 38, 1632-1637	15
954	Changes in renal artery dimensions are associated with clinical response to radiofrequency renal denervation: a series of studies using quantitative angiography and intravascular ultrasound. 2017 , 35, 2069-2076	2
953	Sympathetic Response and Outcomes Following Renal Denervation in Patients With Chronic Heart Failure: 12-Month Outcomes From the Symplicity HF Feasibility Study. 2017 , 23, 702-707	28
952	Threats to internal validity in renal sympathetic denervation trials. 2017 , 36, 353-355	
951	Does dysfunction of the autonomic nervous system affect success of renal denervation in reducing blood pressure?. 2017 , 5, 2050312117702031	0
950	Should We Be Ablating the Kidneys or the Heart to Prevent Arrhythmias?. 2017 , 2, 194-196	
949	From evidence-based medicine to personalized medicine, with particular emphasis on drug-safety monitoring. 2017 , 110, 413-419	5
948	Hypotensive effects of renal denervation in spontaneously hypertensive rat based on ultrasonic contrast imaging. 2017 , 58, 56-61	1
947	Low-dose sustained-release deoxycorticosterone acetate-induced hypertension in Bama miniature pigs for renal sympathetic nerve denervation. 2017 , 11, 314-320	8
946	Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. 2017 , 69, 836-843	59
945	Renal artery and parenchymal changes after renal denervation: assessment by magnetic resonance angiography. 2017 , 27, 3934-3941	5
944	Hypertension up to date: SPRINT to SPYRAL. 2017 , 106, 475-484	16
943	Integrative Blood Pressure Response to Upright Tilt Post Renal Denervation. 2017 , 30, 632-641	2
942	Renal Sympathetic Denervation: A Viable Option for Treating Resistant Hypertension. 2017 , 30, 847-856	8
941	Is renal denervation an alternative or a complement to aldosterone antagonists in treatment of resistant hypertension?. 2017 , 35, 955-957	2
940	Procedural Reassessment of Radiofrequency Renal Denervation in Resistant Hypertensive Patients. 2017 , 24, 187-192	
939	Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?. 2017 , 19, 30	3
938	A comprehensive review of an unmet public health issue: resistant hypertension. 2017 , 39, 101-107	5

937	Renal denervation regulates the atrial arrhythmogenic substrates through reverse structural remodeling in heart failure rabbit model. 2017 , 235, 105-113	18
936	A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence. 2017 , 32, 921-930	13
935	A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failure-Trial design of the REDUCE FMR study. 2017 , 188, 167-174	26
934	Effects of percutaneous renal sympathetic denervation on cardiac function and exercise tolerance in patients with chronic heart failure. 2017 , 36, 45-51	13
933	Autonomic nervous system in acute kidney injury. 2017 , 44, 162-171	14
932	Effect of High Thoracic Sympathetic Nerve Block on Serum Collagen Biomarkers in Patients with Chronic Heart Failure. 2017 , 136, 102-107	5
931	An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. 2017 , 11, 81-91	18
930	Neural Control of Cardiac Function in Health and Disease. 2017 , 13-35	2
929	Potential role of endurance training in altering renal sympathetic nerve activity in CKD?. 2017 , 204, 74-80	10
928	Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry. 2017 , 106, 322-330	20
927	Renal Denervation Reduces Monocyte Activation and Monocyte-Platelet Aggregate Formation: An Anti-Inflammatory Effect Relevant for Cardiovascular Risk. 2017 , 69, 323-331	45
926	Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. 2017 , 130, 439-448.e9	7
925	Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial. 2017 , 70, 1099-1105	31
924	Hypertension on the ROX: Durable Blood Pressure Lowering With Central Iliac Arteriovenous Anastomosis. 2017 , 70, 1084-1086	2
923	The Placebo Effect in Cardiology: Understanding and Using It. 2017 , 33, 1535-1542	10
922	Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?. 2017 , 26, 319-320	0
921	Renal Denervation: Current Opinions and Practice. 2017 , 419-426	
920	New treatment paradigms for ADPKD: moving towards precision medicine. 2017 , 13, 750-768	39

919	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. 2017 , 19, 1361-1378	73
918	Should we take renal denervation with a grain of salt?. 2017 , 19, 1134-1136	3
917	Targeting neural reflex circuits in immunity to treat kidney disease. 2017 , 13, 669-680	41
916	Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial. 2017 , 6,	18
915	Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of 'Nepriylsin' Activity in the Kidney. 2017 , 70, 2139-2153	43
914	Renal Denervation After the SPYRAL HTN-OFF MED Trial: Putting a Complex Study Into Context. 2017 , 70, 1076-1079	5
913	The Impact on Central Blood Pressure and Arterial Stiffness Post Renal Denervation in Patients With Stage 3 and 4 Chronic Kidney Disease: The Prairie Renal Denervation Study. 2017 , 4, 2054358117719028	
912	Renal Denervation Suppresses Coronary Hyperconstricting Responses After Drug-Eluting Stent Implantation in Pigs In Vivo Through the Kidney-Brain-Heart Axis. 2017 , 37, 1869-1880	11
911	Renal denervation decreases susceptibility of the heart to ventricular fibrillation in a canine model of chronic kidney disease. 2017 , 102, 1414-1423	2
910	The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). 2017 , 26, 366-380	8
909	Renal denervation: will the Phoenix rise from the ashes?. 2017 , 38, 3321-3323	1
908	From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research. 2017 , 70, 1121-1133	5
907	Renal Nerves and Long-Term Control of Arterial Pressure. 2017 , 7, 263-320	45
906	Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care. 2017 , 7, e016692	7
905	Atrial Fibrillation and Hypertension. 2017 , 70, 854-861	62
904	Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. 2017 , 19, 1125-1133	5
903	Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. 2017 , 390, 2655-2661	56
902	Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension. 2017 , 6,	37

901	Role of Volume Redistribution in the Congestion of Heart Failure. 2017 , 6,	67
900	Adaptive servo ventilation for central sleep apnoea in heart failure: SERVE-HF on-treatment analysis. 2017 , 50,	19
899	Stretching the carotid sinus to treat resistant hypertension. 2017 , 390, 2610-2612	2
898	Efficacy and safety of renal denervation for Chinese patients with resistant hypertension using a microirrigated catheter: study design and protocol for a prospective multicentre randomised controlled trial. 2017 , 7, e015672	2
897	[Baroreceptor activation therapy for therapy-resistant hypertension: indications and patient selection : Recommendations of the BAT consensus group 2017]. 2017 , 58, 1114-1123	5
896	Threats to internal validity in renal sympathetic denervation trials. 2017 , 36, 353-355	
895	Renal safety of catheter-based renal denervation: systematic review and meta-analysis. 2017 , 32, 1440-1447	22
894	Acute changes in histopathology and intravascular imaging after catheter-based renal denervation in a porcine model. 2017 , 90, 631-638	6
893	Effects of long term device-guided slow breathing on sympathetic nervous activity in hypertensive patients: a randomized open-label clinical trial. 2017 , 26, 359-365	8
892	Reconsidering Renal Sympathetic Denervation for Heart Failure. 2017 , 2, 282-284	1
891	Extravascular renal denervation ameliorates juvenile hypertension and renal damage resulting from experimental hyperleptinemia in rats. 2017 , 35, 2537-2547	5
890	Improvement of Myocardial Function Following Catheter-Based Renal Denervation in Heart Failure. 2017 , 2, 270-281	7
889	Changes in albumin-to-creatinine ratio at 12-month follow-up in patients undergoing renal denervation. 2017 , 36, 343-351	7
888	Changes in albumin-to-creatinine ratio at 12-month follow-up in patients undergoing renal denervation. 2017 , 36, 343-351	3
887	[Arterial Hypertension - Update 2017]. 2017 , 142, 1128-1132	
886	Nerven der Niere. 2017 , 12, 290-293	
885	11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension. 2017 , 30, 518-523	5
884	Catheter-based renal denervation and renal function: no evidence of harm but is there a hope of nephroprotection?. 2017 , 32, 1437-1439	2

883	Predictive factors for successful renal denervation: should we use them in clinical trials?. 2017 , 47, 860-867	4
882	Decoding resistant hypertension signalling pathways. 2017 , 131, 2813-2834	7
881	SPYRAL HTN-OFF MED study: Renal denervation in the spiral orbits of current results and future studies. 2017 , 58, 320-321	2
880	Secondary Causes: Work-Up and Its Specificities in CKD: Influence of Autonomic Dysfunction. 2017 , 149-168	
879	Public Health Efforts for Earlier Resistant Hypertension Diagnosis, Reduction of Salt Content in Food, Promotion of the Use of Polypills to Facilitate Better Adherence, and Reimbursement Policies. 2017 , 233-257	
878	Devices for Neural Modulation (Renal Denervation, Barostimulation). 2017 , 307-321	
877	Renal sympathetic denervation resurrected; or NOT?. 2017 , 11, 700-703	
876	Resistant Hypertension in Chronic Kidney Disease. 2017 ,	0
875	De la investigaci3n no cl3nica a los ensayos y registros cl3nicos: retos y oportunidades en la investigaci3n biom3dica. 2017 , 70, 1121-1133	14
874	Renal Denervation to Modify Hypertension and the Heart Failure State. 2017 , 6, 453-464	1
873	[Systematic errors in clinical studies : A ´comprehensive survey]. 2017 , 114, 215-223	
872	[Systematic errors in clinical studies : A ´comprehensive survey]. 2017 , 76, 71-82	1
871	Systematische Fehler in klinischen Studien. 2017 , 14, 106-116	
870	Renal denervation attenuates hypertension but not salt sensitivity in ET receptor-deficient rats. 2017 , 313, R425-R437	10
869	High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. 2017 , 192, 76-84	1
868	Molecular Mechanisms of Sodium-Sensitive Hypertension in the Metabolic Syndrome. 2017 , 19, 60	9
867	I-mIBG scintigraphy: Clinical tool for assessing renal sympathetic activity?. 2017 , 24, 372-376	1
866	Effect of applied energy in renal sympathetic denervation with magnetic resonance guided focused ultrasound in a porcine model. 2017 , 5, 16	3

865	The Immunology of Cardiovascular Homeostasis and Pathology. 2017,	7
864	Diagnosis and management of resistant hypertension. 2017, 103, 1295-1302	17
863	Atherosclerosis. 2017, 1003, 121-144	37
862	Effects of Spironolactone and Renal Denervation Treatment on Blood Pressure and Its Variability-Different Aspects of Hypertension Treatment. 2017, 30, 12-15	1
861	Innovative Approaches to Arrhythmic Storm: The Growing Role of Interventional Procedures. 2017, 33, 44-50	4
860	Pathophysiologic Mechanisms in Heart Failure: Role of the Sympathetic Nervous System. 2017, 353, 27-30	19
859	Can we predict the blood pressure response to renal denervation?. 2017, 204, 112-118	11
858	Evaluating the carotid bodies and renal nerves as therapeutic targets for hypertension. 2017, 204, 126-130	14
857	The future of renal denervation. 2017, 204, 131-138	19
856	Renal simplicity denervation reduces blood pressure and renal injuries in an obesity-induced hypertension dog model. 2017, 44, 1213-1223	7
855	Soluble vascular endothelial growth factor receptor-1 is reduced in patients with resistant hypertension after renal denervation. 2017, 31, 248-252	4
854	Renal Denervation vs. Spironolactone in Resistant Hypertension: Effects on Circadian Patterns and Blood Pressure Variability. 2017, 30, 37-41	12
853	Efficacy and Safety of Renal Sympathetic Denervation on Dogs with Pressure Overload-Induced Heart Failure. 2017, 26, 194-200	4
852	Effects of renal sympathetic denervation on the stellate ganglion and brain stem in dogs. 2017, 14, 255-262	32
851	CNS sites activated by renal pelvic epithelial sodium channels (ENaCs) in response to hypertonic saline in awake rats. 2017, 204, 35-47	10
850	Novel insights into the mechanisms of renal sympathetic denervation-induced neuromodulation in controlling atrial arrhythmias in canines. 2017, 14, 263-264	
849	Eppur Si Muove: The dynamic nature of physiological control of renal blood flow by the renal sympathetic nerves. 2017, 204, 17-24	8
848	Increased arterial stiffness does not respond to renal denervation in an animal model of secondary hypertension. 2017, 2017, 258-261	

847	Interim report suggests that renal denervation appears to decrease ambulatory blood pressure in patients off medications. A story that continues to unfold. 2017 , 11, 699-700		
846	Programmable Hypertension Control: Another Possible Indication for Implanted Pacemakers. 2017 , 6,		1
845	Trials of Patent Foramen Ovale Closure. <i>New England Journal of Medicine</i> , 2017 , 377, 2599-2600	59.2	4
844	Pacemaker-Mediated Programmable Hypertension Control Therapy. 2017 , 6,		8
843	Update From the Field of Renal Sympathetic Denervation: A Focus on Safety Nomenclature Considerations. 2017 , 51, 664-668		0
842	Interactions cardiovascular. 2017 , 13, 6S11-6S15		1
841	Barostimulation bei therapieresistenter arterieller Hypertonie. 2017 , 13, 323-336		
840	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. 2017 , 390, 2160-2170		406
839	Controversies in hypertension management: target blood pressure, renal nerve ablation, ARNIs, and NSAIDs medication. 2017 , 38, 3245-3248		
838	Catheter-based renal denervation for treatment of hypertension. 2017 , 390, 2124-2126		6
837	Blood Pressure Increase during Oxygen Supplementation in Chronic Kidney Disease Patients Is Mediated by Vasoconstriction Independent of Baroreflex Function. 2017 , 8, 186		6
836	Renal Denervation Promotes Atherosclerosis in Hypertensive Apolipoprotein E-Deficient Mice Infused with Angiotensin II. 2017 , 8, 215		4
835	Editorial: Function of Renal Sympathetic Nerves. 2017 , 8, 642		2
834	Renal sympathetic denervation increases renal blood volume per cardiac cycle: a serial magnetic resonance imaging study in resistant hypertension. 2017 , 10, 243-249		3
833	Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms. 2017 , 18,		65
832	Effects of Renal Denervation on Insulin Sensitivity and Inflammatory Markers in Nondiabetic Patients with Treatment-Resistant Hypertension. 2017 , 2017, 6915310		6
831	Acupuncture Attenuates Renal Sympathetic Activity and Blood Pressure via Beta-Adrenergic Receptors in Spontaneously Hypertensive Rats. 2017 , 2017, 8696402		17
830	Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?. 2017 , 16, 66-69		5

829	Account for Clinical Heterogeneity in Assessment of Catheter-based Renal Denervation among Resistant Hypertension Patients: Subgroup Meta-analysis. 2017 , 130, 1586-1594	1
828	Novel approaches for treating hypertension. 2017 , 6, 80	4
827	Perivascular radiofrequency renal denervation lowers blood pressure and ameliorates cardiorenal fibrosis in spontaneously hypertensive rats. 2017 , 12, e0176888	5
826	Autonomic nervous system involvement in pulmonary arterial hypertension. 2017 , 18, 201	59
825	The effect of renal denervation in an experimental model of chronic renal insufficiency, The REmnant kidney Denervation In Pigs study (REDIP study). 2017 , 15, 215	6
824	Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. 2017 , 81, 1337-1345	21
823	European Society of Cardiology (ESC) Annual Congress Report From Barcelona 2017. 2017 , 81, 1758-1763	2
822	Renal denervation using carbon dioxide renal angiography in patients with uncontrolled hypertension and moderate to severe chronic kidney disease. 2017 , 10, 778-782	7
821	Predictive Factors for Efficacy of Catheterbased Renal Denervation with Standard Ablation Catheter in Refractory Hypertension. 2017 , 03,	
820	Radiosurgical Ablation of the Renal Nerve in a Porcine Model: A Minimally Invasive Therapeutic Approach to Treat Refractory Hypertension. 2017 , 9, e1055	6
819	Therapeutic drug monitoring of amlodipine and the Z-FHL/HHL ratio: Adherence tools in patients referred for apparent treatment-resistant hypertension. 2017 , 107, 887-891	5
818	Novel therapeutic targets for hypertension. 2017 , 23, 162-164	
817	Introduction Opportunities and Challenges. 2017 , xix-xxvii	
816	Antihypertensive effect of piperitenone oxide on spontaneously hypertensive rat by regulating calcium balance and reducing endothelin-1 secretion. 2017 , 12, 341	2
815	PREFACE: Is Renal Denervation Effective Option for Management of Hypertension in Asia?. 2017 , 13, 2-5	3
814	Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency. 2018 , 19, 845-851	8
813	MRI-based detection of renal artery abnormalities related to renal denervation by catheter-based radiofrequency ablation in drug resistant hypertensive patients. 2018 , 28, 3355-3361	1
812	The Interactions of the Immune System and the Brain in Hypertension. 2018 , 20, 7	5

811	Safety profile of baroreflex activation therapy (NEO) in patients with resistant hypertension. 2018 , 36, 1762-1769	10
810	Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA. 2018 , 137, 2427-2429	3
809	Hypertension. 2018 , 291-302	1
808	Flow-mediated dilation, nitroglycerin-mediated dilation and their ratio predict successful renal denervation in mild resistant hypertension. 2018 , 107, 611-615	3
807	Predictors for profound blood pressure response in patients undergoing renal sympathetic denervation. 2018 , 36, 1578-1584	10
806	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. 2018 , 20, 634-636	2
805	Accurate Depth of Radiofrequency-Induced Lesions in Renal Sympathetic Denervation Based on a Fine Histological Sectioning Approach in a Porcine Model. 2018 , 11, e005779	14
804	Impact of the SPRINT Trial on Hypertension Management. 2018 , 69, 81-95	3
803	Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: The DENERVHTA (Denervaci3n en Hipertensi3n Arterial) study. 2018 , 20, 69-75	9
802	Pathogenesis of Hypertension and Renal Disease in Obese Children. 2018 , 463-495	
801	Modulation of renal sympathetic innervation: recent insights beyond blood pressure control. 2018 , 28, 375-384	13
800	A New Era of Renal Denervation Trials for Patients With Hypertension?. 2018 , 71, 615-618	
799	Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies. 2018 , 122, 352-368	76
798	Effects of Renal Denervation on Cardiac Structural and Functional Abnormalities in Patients with Resistant Hypertension or Diastolic Dysfunction. 2018 , 8, 1172	1
797	Drug adherence in treatment resistant and in controlled hypertension-Results from the Swedish Primary Care Cardiovascular Database (SPCCD). 2018 , 27, 315-321	1
796	Impact of Renal Denervation on Atrial Arrhythmogenic Substrate in Ischemic Model of Heart Failure. 2018 , 7,	22
795	Resistant hypertension: Renal denervation or intensified medical treatment?. 2018 , 50, 6-11	11
794	Sham-Controlled Trials for Coronary Interventions: Ethically Acceptable and Ethically Important. 2018 , 71, 95-97	

793	Resistant hypertension: a therapeutic challenge. 2018 , 20, 76-78	1
792	The year in cardiology 2017: prevention. 2018 , 39, 345-353	3
791	Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study. 2018 , 32, 487-493	5
790	[Therapy-resistant and therapy-refractory arterial hypertension]. 2018 , 59, 567-579	1
789	Selective vs. Global Renal Denervation: a Case for Less Is More. 2018 , 20, 37	16
788	Successful Use of Renal Denervation in Patients With Loin Pain Hematuria Syndrome-The Regina Loin Pain Hematuria Syndrome Study. 2018 , 3, 638-644	4
787	Diagnosis and management of resistant hypertension: state of the art. 2018 , 14, 428-441	16
786	Stent retriever thrombectomy for acute ischemic stroke: A systematic review and meta-analysis of randomized controlled trials, including THRACE. 2018 , 174, 319-326	6
785	Resistant Hypertension: Trials and Tribulations. 2018 , 71, 772-780	
784	Effects of Multi-Electrode Renal Denervation on Insulin Sensitivity and Glucose Metabolism in a Canine Model of Type 2 Diabetes Mellitus. 2018 , 29, 731-738.e2	8
783	BVS, RDN, IABP: The Afghanistan of interventional cardiology trials. 2018 , 70, 1-3	3
782	Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?. 2018 , 20, 26	5
781	Renal Artery Denervation Due to Refractory Hypertension in a Patient After Kidney Transplantation-3 Years of Observation: A Case Report. 2018 , 50, 3946-3949	0
780	Hypertension. 2018 , 4, 18014	305
779	Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial. 2018 , 107, 642-652	13
778	Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation. 2018 , 36, 1414-1422	14
777	Research and Development of Information and Communication Technology-based Home Blood Pressure Monitoring from Morning to Nocturnal Hypertension. 2016 , 82, 254-73	18
776	Blood pressure response to renal denervation is correlated with baseline blood pressure variability: a patient-level meta-analysis. 2018 , 36, 221-229	12

775	How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example. 2018 , 27, 66-72	6
774	Last nail in the coffin for PCI in stable angina?. 2018 , 391, 3-4	24
773	Magnetic resonance guided renal denervation using active tracking: first in vivo experience in Swine. 2018 , 34, 431-439	3
772	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. 2018 , 20, 508-519	25
771	Bilateral sphenopalatine ganglion block reduces blood pressure in never treated patients with essential hypertension. A randomized controlled single-blinded study. 2018 , 250, 233-239	5
770	Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. 2018 , 36, 680-689	24
769	Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. 2018 , 250, 29-34	4
768	Renal Sympathetic Denervation. 2018 , 1331-1336	
767	Impact of renal denervation on tissue Na content in treatment-resistant hypertension. 2018 , 107, 42-48	11
766	Number of ablated spots in the course of renal sympathetic denervation in CKD patients with uncontrolled hypertension: EnligHTN vs. Standard irrigated cardiac ablation catheter. 2018 , 35, 54-63	
765	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. 2018 , 195, 115-129	39
764	Antifibrillatory effects of renal denervation on ventricular fibrillation in a canine model of pacing-induced heart failure. 2018 , 103, 19-30	3
763	Renal sympathetic denervation in Sweden: a report from the Swedish registry for renal denervation. 2018 , 36, 151-158	18
762	Central arteriovenous anastomosis to treat resistant hypertension. 2018 , 27, 8-15	5
761	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. 2018 , 137, 364-375	140
760	Essentials of Hypertension. 2018 ,	3
759	Prevention and Treatment. 2018 , 101-145	
758	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 71, e127-e248	2178

757	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 71, e13-e115	1567
756	Macrophages under pressure: the role of macrophage polarization in hypertension. 2018 , 191, 45-63	39
755	Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. 2018 , 84, 18-24	32
754	Neuromodulation Therapies for Cardiac Disease. 2018 , 1519-1530	
753	Anatomy and neural remodeling of the renal sympathetic nerve in a canine model and patients with hypertension. 2018 , 36, 2059-2067	1
752	Device Therapies. 2018 , 268-273	
751	Suitability for catheter-based renal denervation-lessons from 'super-responders'. 2018 , 36, 1475-1476	
750	Blood pressure elevation response to radiofrequency energy delivery: one novel predictive marker to long-term success of renal denervation. 2018 , 36, 2460-2470	6
749	Autonomic Control of the Heart. 2018 , 1265-1272	
748	Effects of Renal Denervation via Renal Artery Adventitial Cryoablation on Atrial Fibrillation and Cardiac Neural Remodeling. 2018 , 2018, 2603025	2
747	Renal denervation therapy beyond resistant hypertension. 2018 , 10, 707-713	5
746	Anticipated expansion of a new approach to treating hypertension without medication by catheter-based renal denervation. 2018 , 10, S3266-S3270	1
745	Renal denervation with ultrasound therapy (paradise device) is an effective therapy for systemic hypertension. 2018 , 10, S3060-S3063	3
744	Fine tuning renal denervation. 2018 , 36, 2312-2313	
743	Treatment-Resistant Hypertension: An Update in Device Therapy. 2018 ,	
742	Renale Denervierung zur Hypertonie-Therapie. 2018 , 143, 1592-1594	
741	Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model. 2018 , 36, 2453-2459	6
740	Renal Denervation Prevents Heart Failure Progression Via Inhibition of the Renin-Angiotensin System. 2018 , 72, 2609-2621	48

739	Developing a Computational Model of Renal Nerves and Surgical System for Laparoscopic Renal Denervation. 2018 , 2018, 4524-4527	
738	Renal denervation - can we press the "ON" button again?. 2018 , 14, 321-327	3
737	Renal denervation: back on track. 2018 , 37, 424-425	
736	Arterial and pulmonary hypertension: risk assessment and current pharmacological and interventional management. 2018 , 39, 4127-4131	4
735	Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis. 2018 , 11, 259-266	0
734	The Prevalence of Japanese Outpatients with Hypertension Who Meet the Definition of Treatment Resistant Hypertension and Are Eligible for Enrolment in Clinical Trials of Endovascular Ultrasound Renal Denervation. 2018 , 57, 1-12	4
733	Pathophysiology of cardiovascular disease in diabetes mellitus. 2018 , 7, 4-9	21
732	2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. 2018 , 36, 1953-2041	1262
731	Renal Denervation. 2018 , 72, 528-536	14
730	Predictors for success in renal denervation-a single centre retrospective analysis. 2018 , 8, 15505	2
729	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 138, e484-e594	242
728	Clinical factors predicting blood pressure reduction after catheter-based renal denervation. 2018 , 14, 270-275	1
727	[Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure]. 2018 , 59, 1011-1020	3
726	Renal denervation in hypertension: Towards a true revival?. 2018 , 111, 541-544	1
725	Catheter-based renal denervation: the next chapter begins. 2018 , 39, 4144-4149	15
724	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. 2018 , 72, e53-e90	333
723	Catheter-Based Renal Denervation for Hypertension. 2018 , 20, 93	8
722	Targeted afferent renal denervation reduces arterial pressure but not renal inflammation in established DOCA-salt hypertension in the rat. 2018 , 314, R883-R891	17

721	Modulation of Sympathetic Overactivity to Treat Resistant Hypertension. 2018 , 20, 92	9
720	Epicardial Left Atrial Appendage Exclusion Reduces Blood Pressure in Patients With Atrial Fibrillation and Hypertension. 2018 , 72, 1346-1353	20
719	European Society of Hypertension position paper on renal denervation 2018. 2018 , 36, 2042-2048	24
718	Electrical stimulation of renal nerves for modulating urine glucose excretion in rats. 2018 , 4, 7	3
717	Treatment of Resistant Hypertension: An Update in Device Therapy. 2018 ,	
716	Catheter Ablation: First-Line Therapy for Atrial Fibrillation in Systolic Heart Failure?. 2018 , 4, 636-637	3
715	Design and simulation of novel laparoscopic renal denervation system: a feasibility study. 2018 , 35, 9-18	10
714	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. 2018 , 391, 2346-2355	358
713	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. 2018 , 391, 2335-2345	301
712	Take a blood pressure pill or undergo renal denervation?. 2018 , 391, 2298-2300	5
711	[Renal artery stenosis long time after renal denervation for resistant hypertension]. 2018 , 67, 204-207	1
710	Rationale and evidence for the development of a durable device-based cardiac neuromodulation therapy for hypertension. 2018 , 12, 381-391	1
709	ConfidenHT System for Diagnostic Mapping of Renal Nerves. 2018 , 20, 49	6
708	Ambulatory arterial stiffness index and blood pressure response to renal denervation. 2018 , 36, 1272-1275	2
707	Left ventricular restoration devices post myocardial infarction. 2018 , 23, 871-883	11
706	Hypertension in the Elderly. 2018 , 57-66	
705	Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies. 2018 , 25, 167-176	13
704	Neurogenic hypertension: pathophysiology, diagnosis and management. 2018 , 28, 363-374	20

703	Renal Denervation-Ready for Prime Time!? The Steep SPYRAL Stairs to RADIANCE in Hypertension Treatment. 2018 , 72, 287-290	10
702	Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure. 2018 , 27, 185-187	3
701	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. 2018 , 4, 944-954	4
700	Renin-Angiotensin System and Cardiovascular Functions. 2018 , 38, e108-e116	67
699	Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. 2018 , 35, 899-927	1
698	Hypertension: history and development of established and novel treatments. 2018 , 107, 16-29	15
697	First-in-Man Experience with a Novel Catheter-Based Renal Denervation System of Ultrasonic Ablation in Patients with Resistant Hypertension. 2018 , 29, 1158-1166	2
696	Drug Adherence in Hypertension and Cardiovascular Protection. 2018 ,	2
695	Prevalence and Comorbidities of Resistant Hypertension: A Collaborative Population-Based Observational Study. 2018 , 25, 295-301	9
694	Reduced Renal Mass, Salt-Sensitive Hypertension Is Resistant to Renal Denervation. 2018 , 9, 455	6
693	Pathogenesis of Hypertension. 2018 , 33-51	6
692	Mechanisms of altered renal sodium handling in age-related hypertension. 2018 , 315, F1-F6	7
691	Renal Sympathetic Denervation in Patients with Resistant Hypertension: A Feasibility Study. 2019 , 6, 137-143	3
690	Blood Pressure and Renal Responses to Orthostatic Stress Before and After Radiofrequency Renal Denervation in Patients with Resistant Hypertension. 2018 , 5, 42	4
689	Erythrocyte Salt Sedimentation Assay Does Not Predict Response to Renal Denervation. 2018 , 5, 51	1
688	Role of the Sympathetic Nervous System and Its Modulation in Renal Hypertension. 2018 , 5, 82	66
687	Renal denervation: one step backwards, three steps forward. 2018 , 14, 602-604	3
686	Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario. 2018 , 31, 1156-1163	8

685	Renal sympathetic nerve activity after catheter-based renal denervation. 2018 , 8, 8	7
684	Cardiac magnetic resonance assessment of central and peripheral vascular function in patients undergoing renal sympathetic denervation as predictor for blood pressure response. 2018 , 107, 945-955	9
683	Renal Denervation. 2018 , 1553-1571	
682	Renal Denervation by Transaortic Periarterial Ethanol Injection: An Experimental Study in Porcines. 2018 , 41, 1943-1951	
681	Neural markers and implantable bioelectronic systems for the treatment of hypertension. 2018 , 1, 139-150	1
680	2018 ESC/ESH Guidelines for the management of arterial hypertension. 2018 , 39, 3021-3104	3698
679	Strategies to manage obstructive sleep apnea to decrease the burden of atrial fibrillation. 2018 , 16, 707-713	4
678	Lowering blood pressure in primary care in Vienna (LOW-BP-VIENNA) : A cluster-randomized trial. 2018 , 130, 698-706	1
677	Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis. 2018 , 36, 1614-1621	14
676	Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. 2018 , 7,	7
675	The Use of Precision Medicine to Manage Obstructive Sleep Apnea Treatment in Patients with Resistant Hypertension: Current Evidence and Future Directions. 2018 , 20, 60	4
674	Comparison of standard renal denervation procedure versus novel distal and branch vessel procedure with brachial arterial access. 2019 , 20, 38-42	10
673	Effect of renal denervation on coronary flow reserve in patients with resistant hypertension. 2019 , 39, 15-21	
672	Cellular and molecular mechanisms of kidney fibrosis. 2019 , 65, 16-36	139
671	2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. 2019 , 25, 20	110
670	Neuroimmunomodulation of tissue injury and disease: an expanding view of the inflammatory reflex pathway. 2019 , 5, 13	5
669	Effect of Catheter-Based Renal Denervation on Uncontrolled Hypertension: A Systematic Review and Meta-analysis. 2019 , 94, 1695-1706	9
668	Meta-Analysis of Randomized Controlled Trials of Atrial Fibrillation Ablation With Pulmonary Vein Isolation Versus Without. 2019 , 5, 968-976	3

667	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). 2019 , 42, 1235-1481	468
666	Denervated or Not? That Remains the Question for Renal Denervation. 2019 , 74, 493-494	
665	Future of Hypertension. 2019 , 74, 450-457	47
664	Effects of sympathetic modulation in metabolic disease. 2019 , 1454, 80-89	16
663	Systematische Fehler in klinischen Studien. 2019 , 11, 21-31	
662	Metabolic Syndrome and Salt-Sensitive Hypertension in Polygenic Obese TALLYHO/JngJ Mice: Role of Na/K-ATPase Signaling. 2019 , 20,	7
661	2018 ESC/ESH Guidelines for the management of arterial hypertension. 2019 , 72, 160.e1-160.e78	8
660	Denervaci3 renal. Importancia del conocimiento de la anatom3a del sistema simp3tico renal en el refinamiento de la t3cnica. 2019 , 72, 531-534	7
659	The role of low-level vagus nerve stimulation in cardiac therapy. 2019 , 16, 675-682	9
658	Effect of renal denervation procedure on left ventricular mass, myocardial strain and diastolic function by CMR on a 12-month follow-up. 2019 , 37, 642-650	2
657	Procedural and Anatomical Determinants of Multielectrode Renal Denervation Efficacy. 2019 , 74, 546-554	15
656	Selective Renal Denervation Guided by Renal Nerve Stimulation in Canine. 2019 , 74, 536-545	12
655	Renal denervation ameliorates post-infarction cardiac remodeling in rats through dual regulation of oxidative stress in the heart and brain. 2019 , 118, 109243	3
654	Renal denervation in patients with symptomatic chronic heart failure despite resynchronization therapy 3a pilot study. 2019 , 15, 240-246	1
653	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. 2019 , HYPERTENSIONAHA11913081	12
652	Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. 2019 , 12, 1095-1105	36
651	Renal Sympathetic Denervation: Sparks of Hope With Some Uncertainties. 2019 , 12, 1106-1108	2
650	Renal Denervation: Is It Ready for Prime Time?. 2019 , 21, 80	5

649	Predictors of blood pressure control in patients with resistant hypertension after intensive management in two expert centres: the Brussels-Torino experience. 2019 , 28, 336-344	5
648	Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management. 2019 , 33, 824-836	31
647	Resistant/Refractory Hypertension and Sleep Apnoea: Current Knowledge and Future Challenges. 2019 , 8,	12
646	Stereotactic Radiotherapy for Renal Denervation: To Beam, or Not to Beam?. 2019 , 74, 1710-1713	3
645	Retrons and their applications in genome engineering. 2019 , 47, 11007-11019	35
644	Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: The HOPE Asia Network. 2019 , 21, 1250-1283	65
643	Resistant Hypertension Updated Guidelines. 2019 , 21, 117	10
642	The REDUCE FMR Trial: A Randomized Sham-Controlled Study of Percutaneous Mitral Annuloplasty in Functional Mitral Regurgitation. 2019 , 7, 945-955	62
641	Looking back and thinking forwards - 15 years of cardiology and cardiovascular research. 2019 , 16, 651-660	7
640	Overview of the 2018 US Food and Drug Administration Circulatory System Devices Panel Meeting on Device-Based Therapies for hypertension. 2019 , 20, 891-896	2
639	Noninvasive Stereotactic Radiotherapy for Renal Denervation in a Swine Model. 2019 , 74, 1697-1709	6
638	Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence: A Post Hoc Analysis the DENERHTN Study. 2019 , 74, 1096-1103	8
637	Revisiting Renal Denervation. 2019 , 94, 1665-1667	
636	Renal denervation therapy for hypertension: still on trial. 2019 , 105, 1452-1453	1
635	Joint UK societies' 2019 consensus statement on renal denervation. 2019 , 105, 1456-1463	14
634	Status of Renal Denervation Therapy for Hypertension. 2019 , 139, 601-603	8
633	Pulmonary Artery Denervation: A New, Long-Awaited Interventional Treatment for Combined Pre- and Post-Capillary Pulmonary Hypertension?. 2019 , 12, 285-288	3
632	Repeated cell transplantation and adjunct renal denervation in ischemic heart failure: exploring modalities for improving cell therapy efficacy. 2019 , 114, 9	5

631	Renal denervation for hypertension: what is needed, and what is next. 2019 , 40, 3483-3485	3
630	Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review. 2019 , 73, 3006-3017	37
629	Novel aspects of the role of the liver in carbohydrate metabolism. 2019 , 99, 119-125	11
628	Blunted diuretic and natriuretic responses to acute sodium loading early after catheter-based renal denervation in normotensive sheep. 2019 , 317, R319-R327	4
627	The autonomic nervous system and cardiac arrhythmias: current concepts and emerging therapies. 2019 , 16, 707-726	54
626	Renal denervation. Importance of knowledge of sympathetic nervous system anatomy in refining the technique. 2019 , 72, 531-534	1
625	Sham trials: benefits and risks for cardiovascular research and patients. 2019 , 393, 2104-2106	3
624	Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. 2019 , 12, e007086	5
623	Indications for Percutaneous Coronary Intervention (PCI) in Chronic Total Occlusion (CTO): Have We Reached a DECISION or Do We Continue to EXPLORE After EURO-CTO?. 2019 , 28, 1484-1489	8
622	Obesity, kidney dysfunction and hypertension: mechanistic links. 2019 , 15, 367-385	171
621	Treating Hypertension Using Renal Artery Denervation: Problems and Progress. 2019 , 26, 117-121	
620	The Year in Clinical Hypertension From Other Pages. 2019 , 32, 441-444	
619	Cardiovascular health technology assessment: recommendations to improve the quality of evidence. 2019 , 6, e000930	1
618	Renal Denervation for Resistant Hypertension in the contemporary era: A Systematic Review and Meta-analysis. 2019 , 9, 6200	8
617	Resistant Hypertension: Diagnosis and Management. 2019 , 26, 99-109	4
616	Relevance of Targeting the Distal Renal Artery and Branches with Radiofrequency Renal Denervation Approaches-A Secondary Analysis from a Hypertensive CKD Patient Cohort. 2019 , 8,	3
615	The cardiac autonomic nervous system: A target for modulation of atrial fibrillation. 2019 , 42, 644-652	17
614	Role of Physical Activity, Exercise, and Cardiorespiratory Fitness in the Management of Resistant Hypertension. 2019 , 169-179	

613	Now That Renal Denervation Works, How Do We Proceed?. 2019 , 124, 693-695	11
612	Laparoscopic-based perivascular unilateral renal sympathetic nerve denervation for treating resistant hypertension: a case report. 2019 , 42, 1162-1165	5
611	Safety and Efficacy of a New Renal Denervation Catheter in Hypertensive Patients in the Absent of Antihypertensive Medications: A Pilot Study. 2019 , 2019, 7929706	6
610	Autonomic Nervous System Dysfunction: JACC Focus Seminar. 2019 , 73, 1189-1206	62
609	Catheter Ablation for Atrial Fibrillation: Lessons Learned From CABANA. 2019 , 321, 1255-1257	8
608	Update on heart failure management and future directions. 2019 , 34, 11-43	48
607	Acute changes in morphology and renal vascular relaxation function after renal denervation using temperature-controlled radiofrequency catheter. 2019 , 19, 67	3
606	Arterial Destiffening Starts Early after Renal Artery Denervation. 2019 , 2019, 3845690	2
605	Cardiorenal Syndrome and Heart Failure-Challenges and Opportunities. 2019 , 35, 1208-1219	21
604	Adherence in Hypertension. 2019 , 124, 1124-1140	172
603	Metabolic Surgery for Hypertension in Patients With Obesity. 2019 , 124, 1009-1024	22
602	Hypertension and Heart Failure. 2019 ,	
601	Renal Nerve Ablation. 2019 , 377-389	
600	Neural Mechanisms. 2019 , 71-86	
599	Device-Based Neuromodulation for Resistant Hypertension Therapy. 2019 , 124, 1071-1093	30
598	Patient preference for therapies in hypertension: a cross-sectional survey of German patients. 2019 , 108, 1331-1342	17
597	Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension. 2019 , 73, 1633-1642	44
596	Anatomic Conformation of Renal Sympathetic Nerve Fibers in Living Human Tissues. 2019 , 9, 4831	5

595	Randomized controlled trials in surgery and the glass ceiling effect. 2019 , 161, 623-625	4
594	Observation of renal sympathetic nerves by intravascular ultrasound. 2019 , 42, 1092-1094	1
593	Sufficient and Persistent Blood Pressure Reduction in the Final Long-Term Results From SYMPPLICITY HTN-Japan - Safety and Efficacy of Renal Denervation at 3 Years. 2019 , 83, 622-629	22
592	Personalized Medicine and the Treatment of Hypertension. 2019 , 21, 13	14
591	Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience. 2019 , 23, 749-755	7
590	Renal Artery Denervation for Hypertension. 2019 , 21, 7	0
589	Continued Momentum in Catheter-Based Renal Denervation: The More the Merrier-Better Denervation Wins Again. 2019 , 20, 2-3	
588	Selección de lo mejor del año 2018 en denervación simpática renal en el tratamiento de la hipertensión arterial. 2019 , 54, 51-57	2
587	Effect of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment of renal failure and hypertension by the PI3K/AKT pathway. 2019 , 43, 1900-1910	2
586	Renal denervation for hypertension: we've come a long way!. 2019 , 9, 607-608	
585	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. 2019 , 3, 100022	
584	Pragmatic Clinical Trials. 2019 , 1-9	
583	Blood pressure changes after renal denervation are more pronounced in women and nondiabetic patients: findings from the Austrian Transcatheter Renal Denervation Registry. 2019 , 37, 2290-2297	4
582	Management of resistant hypertension. 2019 , 34, 367-375	1
581	ReferencesEfficiency and safety of renal denervation via cryoablation (Cryo-RDN) in Chinese patients with uncontrolled hypertension: study protocol for a randomized controlled trial. 2019 , 20, 653	3
580	Pro-inflammatory Cytokines and Resistant Hypertension: Potential for Novel Treatments?. 2019 , 21, 95	11
579	Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension: 12-month results from the ACHIEVE study. 2019 , 37, 1906-1912	5
578	[Austrian Consensus on High Blood Pressure 2019]. 2019 , 131, 489-590	3

577	Renal sympathetic denervation for treatment of hypertension: where are we now in 2019?. 2019 , 28, 498-506	4
576	Carotid body enlargement in hypertension and other comorbidities evaluated by ultrasonography. 2019 , 37, 1455-1462	6
575	Shaping the future of renal denervation-the relevance of sham-controlled randomized trials and recent meta-analyses. 2019 , 9, 601-606	1
574	Hypertension: Key Biomarkers of Injury and Prognosis. 2019 , 21-40	
573	Hypertension in chronic kidney disease: Nephrology Dialysis Transplantation notable 2017 advances. 2019 , 34, 1-4	16
572	AKI and the Neuroimmune Axis. 2019 , 39, 85-95	6
571	Can we trust observational data for clinical decision-making?. 2019 , 40, 1408-1410	1
570	Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era?. 2019 , 5, 69-80	9
569	Comparison of two different radiofrequency ablation systems for renal artery denervation: Evaluation of short-term and long-term follow up. 2019 , 93, E105-E111	3
568	Safety of catheter-based radiofrequency renal denervation on branch renal arteries in a porcine model. 2019 , 93, 494-502	5
567	Sympathetic overactivity in dialysis patients-Underappreciated and clinically consequential. 2019 , 32, 255-265	
566	The VA Co-operative Studies; The First RCTs in Cardiovascular Disease [A Tribute to Edward D. Freis. 2019 , 75-88	
565	Hypertensive Chronic Kidney Disease. 2019 , 62-72.e6	
564	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. 2019 , 40, 743-751	44
563	It's what's inside that matters: Getting to the source in renal denervation. 2019 , 93, 503-505	
562	Autonomic nerves and circadian control of renal function. 2019 , 217, 58-65	6
561	Changing the paradigm in renal denervation: Is trans-urethral access the key to effective blood pressure reduction?. 2019 , 20, 83-85	2
560	[A (too) successful renal denervation]. 2019 , 68, 61-63	

- 559 Obesity-Hypertension Physiopathology and Treatment: A Forty-Year Retrospect. **2019**, 197-229
- 558 Challenges of differential placebo effects in contemporary medicine: The example of brain stimulation. **2019**, 85, 12-20 33
- 557 Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases. **2019**, 41, 13-24 41
- 556 (Prediction of long-term renal denervation efficacy). **2019**, 61, e378-e384
- 555 A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN). **2019**, 139, 590-600 77
- 554 Renal denervation for mild-moderate treatment-resistant hypertension : A timely intervention?. **2019**, 44, 412-418 5
- 553 Successful renal denervation decreases the platelet activation status in hypertensive patients. **2020**, 116, 202-210 9
- 552 The safety of renal denervation as assessed by optical coherence tomography: pre- and post-procedure comparison with multi-electrode ablation catheter in animal experiment. **2020**, 61, 190-196
- 551 Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. **2020**, 41, 1764-1774 7
- 550 Is renal denervation still a treatment option in cardiovascular disease?. **2020**, 30, 189-195 1
- 549 Does treatment-resistant hypertension exist in children? A review of the evidence. **2020**, 35, 969-976 4
- 548 Renal Artery Branch Denervation: Evaluation of Lesion Characteristics Using a Thermochromic Liquid Crystal Phantom Model. **2020**, 29, 445-451 2
- 547 Resistant hypertension: new insights and therapeutic perspectives. **2020**, 6, 188-193 4
- 546 Renal denervation for the treatment of resistant hypertension in Spain. The Flex-Spyral Registry. **2020**, 73, 615-622
- 545 Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system. **2020**, 109, 513-522 10
- 544 Enhanced arrhythmogenic potential induced by renal autonomic nerve stimulation: Role of renal artery catheter ablation. **2020**, 17, 133-141
- 543 Neuromodulation in Heart Failure. **2020**, 608-616.e2
- 542 Hypertension in Chronic Kidney Disease: Novel Insights. **2020**, 16, 45-54 5

541	Denervaci3n renal para el tratamiento de la hipertensi3n arterial resistente en Espa3a. Registro Flex-Spyral. 2020 , 73, 615-622	3
540	Renal Artery Denervation in Resistant Hypertension: The Good, The Bad and The Future. 2020 , 29, 94-101	7
539	Renal Denervation in the Management of Hypertension: A Meta-Analysis of Sham-Controlled Trials. 2020 , 21, 532-537	4
538	New approaches for treating atrial fibrillation: Focus on autonomic modulation. 2020 , 30, 433-439	5
537	Home Blood Pressure Monitoring. 2020 ,	0
536	Emerging Therapies. 2020 , 1189-1205	
535	Kidney disease trials for the 21st century: innovations in design and conduct. 2020 , 16, 173-185	8
534	Resistant Hypertension: Novel Insights. 2020 , 16, 61-72	12
533	Approaches for the Management of Resistant Hypertension in 2020. 2020 , 22, 3	8
532	Thermal therapy monitoring using elastography. 2020 , 135-155	1
531	Renal denervation: Alternative treatment options for hypertension?. 2020 , 63, 51-57	1
530	Editorial commentary: Renal denervation: The three stages of academic grief. 2020 , 30, 196-197	
529	Crosstalk between the nervous system and the kidney. 2020 , 97, 466-476	28
528	Selective afferent renal denervation mitigates renal and splanchnic sympathetic nerve overactivity and renal function in chronic kidney disease-induced hypertension. 2020 , 38, 765-773	13
527	The Stabilization of Central Sympathetic Nerve Activation by Renal Denervation Prevents Cerebral Vasospasm after Subarachnoid Hemorrhage in Rats. 2020 , 11, 528-540	8
526	Left ventricular hypertrophy and hypertension. 2020 , 63, 10-21	69
525	Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension. 2020 , 177, 1457-1471	13
524	Neurogenic tachykinin mechanisms in experimental nephritis of rats. 2020 , 472, 1705-1717	4

523	Human Dorsal Root Ganglion Stimulation Reduces Sympathetic Outflow and Long-Term Blood Pressure. 2020 , 5, 973-985	5
522	Will the SPYRAL-OFF MED pivotal trial switch our interest in renal denervation back on?. 2020 , 116, e140-e142	
521	Device profile of the MobiusHD EVBA system for the treatment of resistant hypertension: overview of its mechanism of action, safety and efficacy. 2020 , 17, 649-658	0
520	Effect of combined renal denervation and pulmonary vein isolation in atrial fibrillation recurrence in hypertensive patients: A meta-analysis. 2020 , 43, 866-874	4
519	Treatment of resistant hypertension. 2020 , 16, 353-356	
518	Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. 2020 , 41, 2556-2569	7
517	How important are placebo controls in clinical trials of interventional procedures?. 2020 , 41, 2569-2570	1
516	Bariatric Surgery for Resistant Hypertension: Working in Progress!. 2020 , 22, 55	2
515	Development of a nitinol-actuated surgical instrument for laparoscopic renal denervation: feasibility test in a swine survival model. 2020 , 37, 573-584	2
514	Arterial hypertension: New concepts in diagnosis and treatment?. 2020 , 61, 145-147	2
513	Renal denervation: where do we stand and what is the relevance to the nephrologist?. 2020 ,	7
512	Quantitative analysis of renal arterial variations affecting the eligibility of catheter-based renal denervation using multi-detector computed tomography angiography. 2020 , 10, 19720	4
511	Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension : A Randomized Clinical Trial. 2020 , 173, 685-693	27
510	Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension. 2020 , 9,	4
509	Extended Renal Artery Denervation Is Associated with Artery Wall Lesions and Acute Systemic and Pulmonary Hemodynamic Changes: A Sham-Controlled Experimental Study. 2020 , 2020, 8859663	2
508	Kidney Disease in the Cardiac Catheterization Laboratory. 2020 ,	
507	Dopamine Hydroxylase as a potential drug target to combat hypertension. 2020 , 29, 1043-1057	8
506	Special Article - The management of resistant hypertension: A 2020 update. 2020 , 63, 662-670	2

505	Flow field study of radiofrequency ablation of renal sympathetic nerve: Numerical simulation and PIV experiments. 2020 , 39, 262-272	2
504	Renal denervation: An uncertain future. 2020 , 21, 1470320320936094	
503	Sympathomodulation in congestive heart failure: From drugs to devices. 2020 , 321, 118-125	2
502	Renal denervation in South Africa. 2020 , 110, 12841	
501	Recent trends in renal denervation devices for resistant hypertension treatment. 2021 , 190, 971-979	0
500	A Resource-Optimized Patient-Specific Nonlinear-SVM Hypertension Detection Algorithm for Minimally-Invasive High Blood Pressure Control. 2020 ,	
499	Effect of renal denervation on catecholamines and the renin-angiotensin-aldosterone system. 2020 , 21, 1470320320943095	3
498	A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy. 2020 , 22, 85	3
497	Renal Denervation for Resistant Hypertension: Where Do We Stand?. 2020 , 22, 83	3
496	Development and Evaluation of a Disease Large Animal Model for Preclinical Assessment of Renal Denervation Therapies. 2020 , 10,	
495	Quantification of Renal Sympathetic Vasomotion as a Novel End Point for Renal Denervation. 2020 , 76, 1247-1255	3
494	Clinical outcomes of laparoscopic-based renal denervation plus adrenalectomy vs adrenalectomy alone for treating resistant hypertension caused by unilateral aldosterone-producing adenoma. 2020 , 22, 1606-1615	6
493	Microdissection of the Human Renal Nervous System: Implications for Performing Renal Denervation Procedures. 2020 , 76, 1240-1246	13
492	Renal Denervation in Hypertensive Patients: Back to Anatomy?. 2020 , 76, 1084-1086	3
491	Renal Denervation: History and Current Status. 2020 , 9, 483-488	
490	Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations. 2020 , 16, 769-785	10
489	Clinical benefits and safety of renal denervation in severe arterial hypertension: A long-term follow-up study. 2020 , 22, 1854-1864	3
488	Renal Denervation for Resistant Hypertension: Time to Improve Patient Selection. The Lesson From ADPKD. 2020 , 7, 604384	

487	Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges. 2020 , 7, 582634	1
486	Indian guidelines on hypertension-IV (2019). 2020 , 34, 745-758	24
485	Hypertension Canada's 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension. 2020 , 36, 625-634	13
484	2A-Adrenoceptors Modulate Renal Sympathetic Neurotransmission and Protect against Hypertensive Kidney Disease. 2020 , 31, 783-798	6
483	Laparoscopic based renal denervation in a canine neurogenic hypertension model. 2020 , 20, 285	1
482	Autonomic Control of the Heart and Its Clinical Impact. A Personal Perspective. 2020 , 11, 582	7
481	Hypertension in obesity. 2020 , 35, 389-396	12
480	Renal iodine-metaiodobenzylguanidine scintigraphy relates to muscle sympathetic nervous activity in heart failure with reduced ejection fraction. 2020 , 226, 102671	
479	Renal Sympathetic Denervation for Hypertension: Outside-In and Inside-Out. 2020 , 21, 538-539	1
478	Evaluation of Transcatheter Alcohol-Mediated Perivascular Renal Denervation to Treat Resistant Hypertension. 2020 , 9,	2
477	Estrogen-related mechanisms in sex differences of hypertension and target organ damage. 2020 , 11, 31	26
476	Renal Denervation and International Registry Data: Where Are We Now?. 2020 , 75, 2889-2891	1
475	Laparoscopic-based perivascular renal sympathetic nerve denervation: a feasibility study in a porcine model. 2020 , 25, 22	3
474	Italian Society of Arterial Hypertension (SIIA) Position Paper on the Role of Renal Denervation in the Management of the Difficult-to-Treat Hypertensive Patient. 2020 , 27, 109-117	7
473	Comparison of Radio Frequency Current and Microwave Energy for Transcatheter Renal Denervation. 2020 , 4, 89-96	2
472	Registries in renal denervation-completing the picture?. 2020 , 73, 605-607	
471	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. 2020 , 395, 1444-1451	166
470	Impact of electrical cardioversion on quality of life for patients with symptomatic persistent atrial fibrillation: Is there a treatment expectation effect?. 2020 , 226, 152-160	1

469	Activated double-negative T cells (CD3CD4CD8HLA-DR) define response to renal denervation for resistant hypertension. 2020 , 218, 108521	2
468	Sleep Apnea, Hypertension and the Sympathetic Nervous System in the Adult Population. 2020 , 9,	17
467	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. 2020 , 13, 471-484	30
466	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. 2020 , 109, 289-302	15
465	The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. 2020 , 13, 461-470	23
464	Continued Evolution of Renal Artery Denervation for Hypertension. 2020 , 13, 485-487	0
463	Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension. 2020 , 30, 541-548	0
462	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. 2020 , 22, 572-584	17
461	Renal sympathetic nerve activity regulates cardiovascular energy expenditure in rats fed high salt. 2020 , 43, 482-491	10
460	Improving Outcomes in Patients With Atrial Fibrillation and Hypertension. 2020 , 323, 221-222	
459	Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. 2020 , 323, 248-255	70
458	Renal Denervation in Asia: Consensus Statement of the Asia Renal Denervation Consortium. 2020 , 75, 590-602	22
457	Assessment and treatment of resistant hypertension. 2020 , 31, 19-22	
456	. 2020 , 162, 18	
455	Low-Level Tragus Stimulation for Atrial Fibrillation: A Glimpse of Hope for Neuromodulation?. 2020 , 6, 292-294	3
454	Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. 2020 , 41, 1588-1599	41
453	Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis. 2020 , 38, 936-942	11
452	Renal Denervation in Daily Practice: If So, How?. 2020 , 27, 267-270	1

451	Resistant Hypertension in a Patient With Chronic Type B Aortic Dissection. A Selective Indication for Renal Artery Denervation Treatment. 2020 , 33, 784-787	0
450	Laparoscopic Renal Denervation System for Treating Resistant Hypertension: Overcoming Limitations of Catheter-Based Approaches. 2020 , 67, 3425-3437	4
449	Device-based therapies for arterial hypertension. 2020 , 17, 614-628	35
448	Is There Any Role for Device Therapies in Resistant Hypertension? Commentary.. 2020 , 1, 14-15	
447	Influence of pre-treatment blood pressure levels on antihypertensive drug benefits in diabetics: the roadmap experience. 2020 , 29, 247-255	
446	Neuroimmune interactions in cardiovascular diseases. 2021 , 117, 402-410	11
445	Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction. 2021 , 110, 711-724	1
444	The involvement of renal afferents in the maintenance of cardiorenal diseases. 2021 , 320, R88-R93	1
443	Resistant Hypertension in People With CKD: A Review. 2021 , 77, 110-121	14
442	Renal Denervation to Treat Heart Failure. 2021 , 83, 39-58	9
441	Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine Infusion Catheter. 2021 , 24, 77-86	0
440	The state of renal sympathetic denervation for the management of patients with hypertension: A systematic review and meta-analysis. 2021 , 97, E438-E445	2
439	Contemporary Strategies to Manage High Blood Pressure in Patients with Coexistent Resistant Hypertension and Heart Failure With Reduced Ejection Fraction. 2021 , 10, 9-25	0
438	Recent updates on novel therapeutic targets of cardiovascular diseases. 2021 , 476, 145-155	7
437	Renal Denervation, Come Back Time?. 2021 , 51, 56-57	
436	Splenic denervation attenuates repeated social defeat stress-induced T-lymphocyte inflammation.	
435	Pathophysiology and Epidemiology of Hypertension in Children. 2021 , 1-34	
434	Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: A meta-analysis. 2021 ,	6

433	Laparoscopic Ablation System for Complete Circumferential Renal Sympathetic Denervation. 2021 , 68, 3217-3227	2
432	[Second chance for renal artery denervation]. 2021 , 27, 32-40	
431	Insights on safety and efficacy of renal artery denervation for uncontrolled-resistant hypertension in a high risk population with chronic kidney disease: first Italian real-world experience. 2021 , 34, 1445-1455	3
430	Renal Sympathetic Denervation as Upstream Therapy During Atrial Fibrillation Ablation: Pilot HFIB Studies and Meta-Analysis. 2021 , 7, 109-123	3
429	The organ-specific nitric oxide synthase activity in the interaction with sympathetic nerve activity: a hypothesis. 2021 , 70, 169-175	1
428	AT II Receptor Blockade and Renal Denervation: Different Interventions with Comparable Renal Effects?. 2021 , 46, 331-341	0
427	Improvement of intestinal flora: accompany with the antihypertensive effect of electroacupuncture on stage 1 hypertension. 2021 , 16, 7	6
426	Improved Understanding of Renal Nerve Anatomy: An Opportunity to Enhance Denervation Treatment of Hypertension. 2021 , 14, 316-318	2
425	Renal Denervation and Celiac Ganglionectomy Decrease Mean Arterial Pressure Similarly in Genetically Hypertensive Schlager (BPH/2J) Mice. 2021 , 77, 519-528	6
424	Achieving Optimal Medical Therapy: Insights From the ORBITA Trial. 2021 , 10, e017381	4
423	Renal Denervation for Uncontrolled and Resistant Hypertension: Systematic Review and Network Meta-Analysis of Randomized Trials. 2021 , 10,	2
422	Comprehensive Assessment of Human Accessory Renal Artery Periarterial Renal Sympathetic Nerve Distribution. 2021 , 14, 304-315	4
421	Russian medical society on arterial hypertension (RMSAH) Consensus of Experts on the use of radiofrequency denervation of the renal arteries in patients with arterial hypertension. 2020 , 17, 7-18	5
420	Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The Reshape CV-Risk Study. 2021 , 23, 954-962	1
419	The Development of a Novel Percutaneous Treatment for Secondary Mitral Regurgitation The Carillon Mitral Contour System . 2021 , 153-162	
418	Renal Sympathetic Denervation: A Comprehensive Review. 2021 , 46, 100598	7
417	Neurogenic substance P-influences on action potential production in afferent neurons of the kidney?. 2021 , 473, 633-646	1
416	The current status of renal denervation for the treatment of arterial hypertension. 2021 , 65, 76-83	5

415	Role of the sympathetic nervous system in cardiometabolic control: implications for targeted multiorgan neuromodulation approaches. 2021 , 39, 1478-1489	1
414	Evidence of Reduced Efferent Renal Sympathetic Innervation After Chemical Renal Denervation in Humans. 2021 , 34, 744-752	3
413	Arterielle Hypertonie [Was war 2020 wichtig?]. 2021 , 15, 127-132	0
412	Increase in Bioavailability of Nitric Oxide After Renal Denervation Improves Kidney Function in Sheep With Hypertensive Kidney Disease. 2021 , 77, 1299-1310	3
411	Device Therapy of Hypertension. 2021 , 128, 1080-1099	6
410	New Drugs and Interventional Strategies for the Management of Hypertension. 2021 , 27, 1396-1406	0
409	The Effects of Renal Nerve Denervation on Blood Pressure and Target Organs in Different Hypertensive Rat Models. 2021 , 2021, 8615253	1
408	Catheter-Based Radiofrequency Renal Sympathetic Denervation Decreases Left Ventricular Hypertrophy in Hypertensive Dogs. 2021 , 2021, 9938486	1
407	Open-loop analysis on sympathetically mediated arterial pressure and urine output responses in spontaneously hypertensive rats: effect of renal denervation. 2021 , 71, 13	0
406	Metabolic effects two years after renal denervation in insulin resistant hypertensive patients. The Re-Shape CV-risk study. 2021 , 40, 1503-1509	1
405	Clinical Trial Designs for Neuromodulation in Chronic Spinal Cord Injury Using Epidural Stimulation. 2021 , 24, 405-415	1
404	Renal interventions in the management of hypertension. 2021 , 36, 444-452	
403	Joint ESH excellence centers' national meeting on renal sympathetic denervation: A Greek experts' survey. 2021 , 62, 355-358	1
402	The Road to Better Management in Resistant Hypertension-Diagnostic and Therapeutic Insights. 2021 , 13,	0
401	Renal Arteries Revisited: Anatomy, Pathologic Entities, and Implications for Endovascular Management. 2021 , 41, 909-928	
400	Hypertension: Current trends and future perspectives. 2021 , 87, 3721-3736	2
399	Update on Treatment of Hypertension After Renal Transplantation. 2021 , 23, 25	0
398	Renal Sympathetic Denervation Using a Novel Device: A Clinical Case Discussion and Literature Update. 2021 ,	

397	Neuroscientific therapies for atrial fibrillation. 2021 , 117, 1732-1745	4
396	[Update on treatment resistant hypertension and secondary hypertension]. 2021 , 146, 742-746	
395	Renal denervation in patients with versus without chronic kidney disease: results from the global SYMPPLICITY Registry with follow-up data of 3 years. 2021 ,	6
394	Renal Denervation Exacerbates LPS- and Antibody-induced Acute Kidney Injury, but Protects from Pyelonephritis in Mice. 2021 , 32, 2445-2453	0
393	Importance of the renal ion channel TRPM6 in the circadian secretion of renin to raise blood pressure. 2021 , 12, 3683	1
392	Re-evaluating absent clinical success after adrenalectomy in unilateral primary aldosteronism. 2021 , 170, 1389-1396	2
391	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. 2021 , 397, 2476-2486	47
390	Mapping Renal Innervations by Renal Nerve Stimulation and Characterizations of Blood Pressure Response Patterns. 2021 , 1	2
389	European Society of Hypertension position paper on renal denervation 2021. 2021 , 39, 1733-1741	21
388	Responsiveness of afferent renal nerve units in renovascular hypertension in rats. 2021 , 473, 1617-1629	0
387	Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. 2021 , 39, 1742-1767	15
386	Arterial hypertension. 2021 , 398, 249-261	13
385	Monitoring Antihypertensive Medication Adherence by Liquid Chromatography-Tandem Mass Spectrometry: Method Establishment and Clinical Application. 2021 , 78, 581-596	1
384	Renal Denervation for Patients With Atrial Fibrillation. 2021 , 23, 126	1
383	Renal denervation does not affect hypertension or the renin-angiotensin system in a rodent model of juvenile-onset polycystic kidney disease: clinical implications. 2021 , 11, 14286	2
382	Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints: Tailoring Therapy. 2021 , 39, 377-387	1
381	An Update on Catheter-Based Renal Denervation for the Treatment of Hypertension. 2021 , 15, 1	
380	Renal sympathetic denervation in patients with resistant hypertension. Results of long-term prospective follow-up. 2021 , 27, 318-332	3

- 379 A Japan nationwide web-based survey of estimation on patients for renal denervation based on blood pressure level and the number of antihypertensives (J-NEEDs survey). **2021**, 23, 1684-1694 1
- 378 Effect of Exercise Training on Ambulatory Blood Pressure Among Patients With Resistant Hypertension: A Randomized Clinical Trial. **2021**, 6, 1317-1323 6
- 377 Renal denervation as a management strategy for hypertension: current evidence and recommendations. **2021**, 19, 825-835
- 376 Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. **2021**, 98, 416-426 5
- 375 Endovascular denervation (EDN): From Hypertension to Non-Hypertension Diseases. **2021**, 4, 130-135
- 374 Pacemaker-Based Cardiac Neuromodulation Therapy in Patients With Hypertension: A Pilot Study. **2021**, 10, e020492 2
- 373 Renal denervation prevents myocardial structural remodeling and arrhythmogenicity in a chronic kidney disease rabbit model. **2021**, 18, 1596-1604 1
- 372 Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial. **2021**, 144, 1212-1226 5
- 371 Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. **2021**, 239, 90-99 4
- 370 Autonomic modulation of ventricular electrical activity: recent developments and clinical implications. **2021**, 31, 659-676 0
- 369 Paradise[®] Ultrasound Renal Denervation System for the treatment of hypertension. **2021**, 17, 931-944
- 368 Splenic denervation attenuates repeated social defeat stress-induced T-lymphocyte inflammation.. **2021**, 1, 190-200 0
- 367 Catheter-Based Alcohol-Mediated Renal Denervation for Treating Resistant Hypertension: Is the Peregrine Predator or Prey?. **2021**, 14, e011293
- 366 Renal denervation based on experimental rationale. **2021**, 44, 1385-1394 6
- 365 RADIANCE-HTN TRIO: how the saga of renal denervation revisits hypertension therapy. **2021**, 117, e141-e143 1
- 364 Trattamento endovascolare delle lesioni delle arterie renali. **2021**, 26, 1-13
- 363 New directions for sympathetic denervation. **2021**, 18, 1758-1759
- 362 Impact of renal sympathetic denervation on cardiac magnetic resonance-derived cardiac indices in hypertensive patients - A meta-analysis. **2021**, 78, 314-321 0

361	Differential influences of dietary sodium on blood pressure regulation based on race and sex. 2021 , 236, 102873	2
360	Hypertension. 2022 , 377-386	
359	Current Status and Future Perspectives of Renal Denervation. 2021 , 51, 717-732	1
358	Effects of catheter-based renal denervation on glycemic control and lipid levels: a systematic review and meta-analysis. 2021 , 58, 603-614	5
357	?????????:?????????????. 2021 , 30, 11-19	
356	Renal Denervation in Hypertension. 2021 , 17, 73-74	
355	Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model. 2021 , 52, 429-434	0
354	Circular radio-frequency electrode with MEMS temperature sensors for laparoscopic renal sympathetic denervation. 2021 , PP,	1
353	Hypertension trials update. 2021 , 35, 398-409	4
352	Comparison of a 5 F Microtube-Irrigated Ablation Catheter and a General Ablation Catheter in the Treatment of Resistant Hypertension with Renal Denervation. 2021 ,	
351	An Open-label, Single-arm, Multicenter Feasibility Study Evaluating the Safety of Catheter-based Renal Denervation with DENEXIn Patients with Uncontrolled Hypertension on Standard Medical Therapy. 2021 , 51, 43-55	2
350	Main Renal Artery Plus Branch Ablation in the Treatment of Resistant Hypertension with Renal Denervation. 2021 ,	
349	Data Collection and Quality Control. 2015 , 233-253	3
348	Ethical Issues. 2015 , 25-48	2
347	Regulatory Issues. 2015 , 519-542	2
346	Blinding. 2015 , 147-163	1
345	Home (Self) Monitoring of Blood Pressure in Clinical Trials. 2016 , 353-369	5
344	Carotid Baroreceptor Stimulation. 2016 , 339-348	1

343	Directly Observed Therapy in Hypertension (DOT-HTN). 2018 , 57-85	3
342	Role of the Nervous System in Acute Kidney Injury. 2020 , 297-316	1
341	Rigor in Biomedical Science. 2017 , 41-43	1
340	ISCHEMIA: A Search for clarity and why we may not find it. 2018 , 203, 82-84	3
339	Resolution of drug-resistant hypertension by adrenal vein sampling-guided adrenalectomy: a proof-of-concept study. 2020 , 134, 1265-1278	4
338	Renal denervation for severe hypertension in a small child with Turner syndrome: miniaturisation of the procedure and results. 2015 , 2015,	5
337	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. 2021 , 143, 479-500	34
336	Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. 2020 , 76, 1410-1417	18
335	2019 Chinese guideline for the management of hypertension in the elderly. 2019 , 16, 67-99	28
334	Recent advances in understanding and managing resistant/refractory hypertension. 2020 , 9,	3
333	Recent advances in the management of resistant hypertension. 2015 , 7, 03	2
332	The Effects of Renal Denervation on Renal Hemodynamics and Renal Vasculature in a Porcine Model. 2015 , 10, e0141609	4
331	Renal Denervation Suppresses the Inducibility of Atrial Fibrillation in a Rabbit Model for Atrial Fibrosis. 2016 , 11, e0160634	10
330	Renal Denervation After Symplicity HTN-3 - Back to Basics. Review of the Evidence. 2014 , 9, 110-114	2
329	Hypertension in Chronic Kidney Disease - Role of Arterial Calcification and Impact on Treatment. 2014 , 9, 115-119	9
328	Lessons Learned from RADIOSOUND-HTN: Different Technologies and Techniques for Catheter-based Renal Denervation and Their Effect on Blood Pressure. 2019 , 14, 102-106	1
327	Arterial hypertension in adults. Clinical guidelines 2020. 2020 , 25, 3786	155
326	Renal denervation attenuates aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension. 2016 , 7, 67828-67840	23

325	Neuromodulation Therapy in Heart Failure: Combined Use of Drugs and Devices. 2020 , 11, 4151-4159	2
324	Initial Experience with Renal Denervation for the Treatment of Resistant Hypertension - The Utility of Novel Anesthetics and Metaiodobenzylguanidine Scintigraphy (MIBG). 2016 , 10, 163-70	1
323	Renal sodium handling and sodium sensitivity. 2017 , 36, 117-131	15
322	Radiofrequency denervation of the renal arteries in patients with resistant arterial hypertension: 3 years of observation experience. 2019 , 16, 65-69	2
321	Renal denervation with a resistant arterial hypertension: the results of a five-year follow-up. 2018 , 90, 88-91	2
320	Renal denervation in 2019. 2019 , 34, 21-32	3
319	Hypertension as a persistent public health problem. A position paper from Alliance for a Healthy Heart, Mexico. 2019 , 3, 009-030	4
318	Renal sympathetic denervation improves cardiac dysfunction in rats with chronic pressure overload. 2015 , 64, 653-62	21
317	Early morphologic alterations in renal artery wall and renal nerves in response to catheter-based renal denervation procedure in sheep: difference between single-point and multiple-point ablation catheters. 2017 , 66, 601-614	6
316	Evaluation of later morphologic alterations in renal artery wall and renal nerves in response to catheter-based renal denervation in sheep: comparison of the single-point and multiple-point ablation catheters. 2018 , 67, 891-901	2
315	Proposal for a graded approach to disclosure of interests in accredited CME/CPD. 2015 , 4, 29894	3
314	A 2020 Vision of Hypertension. 2020 , 50, 469-475	9
313	Resistant hypertension: an approach to management in primary care. 2015 , 4, 193-9	26
312	Renal denervation by CT-guided periarterial injection of hyperosmolar saline, vincristine, paclitaxel and guanethidine in a pig model. 2017 , 12, e2262-e2270	2
311	Serial quantitative magnetic resonance angiography follow-up of renal artery dimensions following treatment by four different renal denervation systems. 2017 , 12, e2271-e2277	2
310	Comparison of new-generation renal artery denervation systems: assessing lesion size and thermodynamics using a thermochromic liquid crystal phantom model. 2017 , 13, 1242-1247	6
309	Evaluating the importance of sham-controlled trials in the investigation of medical devices in interventional cardiology. 2018 , 14, 708-715	5
308	Safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients. 2018 , 14, e1334-e1342	15

307	Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. 2020 , 16, 89-96	24
306	Renal denervation reloaded: where to go from here?. 2015 , 10, 1135-7	3
305	Bipolar multi-electrode balloon catheter radiofrequency renal denervation with the Vessix system: preclinical safety evaluation. 2015 , 10, 1239-46	2
304	From SYMPLICITY HTN-3 to the renal denervation global registry: where do we stand and where should we go?. 2014 , 10, 21-3	21
303	Renal denervation revisited: comparative appraisal of safety and efficacy. 2014 , 10, 178-80	1
302	Renal denervation with cryoenergy as second-line option is effective in the treatment of resistant hypertension in non-responders to radiofrequency ablation. 2014 , 10, 640-5	16
301	Symplcity multi-electrode radiofrequency renal denervation system feasibility study. 2015 , 11, 104-9	9
300	Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. 2015 , 11, 110-6	32
299	Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity. 2015 , 11, 477-84	30
298	Intraprocedural reduction of the veno-arterial norepinephrine gradient correlates with blood pressure response after renal denervation. 2015 , 11, 824-34	2
297	Endovascular ultrasound for renal sympathetic denervation in patients with therapy-resistant hypertension not responding to radiofrequency renal sympathetic denervation. 2016 , 12, e282-9	11
296	Invasive aortic pulse wave velocity as a marker for arterial stiffness predicts outcome of renal sympathetic denervation. 2016 , 12, e684-92	27
295	Controlled circumferential renal sympathetic denervation with preservation of the renal arterial wall using intraluminal ultrasound: a next-generation approach for treating sympathetic overactivity. 2015 , 10, 1230-8	34
294	Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. 2015 , 10, 1213-20	46
293	Twelve-month results of the rapid renal sympathetic denervation for resistant hypertension using the OneShot™ ablation system (RAPID) study. 2015 , 10, 1221-9	28
292	First-in-man radial access renal denervation with the ReCor Radiance™ catheter. 2015 , 10, 1209-12	4
291	Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications. 2018 , 14, e598-e602	2
290	Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications. 2018 , 14, e603-e606	2

289	Will ORBITA change my practice? ORBITA trial: Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina. 2018 , 14, 951-954	1
288	Transcatheter therapies for resistant hypertension: Clinical review. 2014 , 6, 706-12	1
287	Renal sympathetic denervation in therapy resistant hypertension - pathophysiological aspects and predictors for treatment success. 2016 , 8, 436-46	7
286	Effect of renal denervation on glucose metabolism after a 12 month follow-up. 2015 , 159, 246-50	2
285	Blood pressure and glaucoma: At the crossroads between cardiology and ophthalmology. 2019 , 26, 8-12	3
284	Percutaneous renal artery denervation in patients with chronic systolic heart failure: A randomized controlled trial. 2019 , 26, 503-510	13
283	First reported cases: renal denervation with second-generation multi-electrode catheter via brachial and radial access. 2016 , 27, 53-5	4
282	2019 Consensus Statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on Renal Denervation for the Management of Arterial Hypertension. 2019 , 35, 199-230	10
281	Renal arteries denervation: from the treatment of resistant hypertension to the treatment of atrial fibrillation. 2021 , 23, E177-E183	1
280	Renal nerve stimulation: complete versus incomplete renal sympathetic denervation. 2021 , 30, 376-385	2
279	Technical advance in silico and in vitro development of a new bipolar radiofrequency ablation device for renal denervation. 2021 , 21, 500	
278	Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. 2021 ,	7
277	Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials. 2021 ,	4
276	Role of renal denervation in the treatment of arterial hypertension: a review. 2021 , 26, 4497	1
275	Optimal Strategy for HIFU-Based Renal Sympathetic Denervation in Canines. 2021 , 8, 739560	1
274	Ultrasound renal denervation for hypertension: impact of the RADIANCE-HTN-TRIO trial on future management of resistant hypertension. 2021 ,	
273	A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. 2021 ,	3
272	Fettstoffwechsel und Hypertonie bei Diabetes. 2014 , 217-237	

- 271 Antihypertonika. **2014**, 445-468
- 270 [Re: Renal sympathetic denervation in treatment-resistant hypertension]. **2014**, 134, 1449-50
- 269 Management of the Hypertensive Child. **2014**, 1-87
- 268 [Questionable efficacy of renal denervation]. **2014**, 134, 1643-4
- 267 Treatment resistant hypertension--investigation and conservative management. **2014**, 111, 425-31 12
- 266 Renal Sympathetic Denervation in the Management of Treatment-Resistant Hypertension. **2015**, 181-186
- 265 The role of the vegetative part of sympathetic nervous system in development of cardiovascular complications in patients with arterial hypertension: pharmacological aspects. **2014**, 11, 88-94
- 264 Appraisal of the Clinical Trial Data on Renal Denervation for the Management of Resistant Hypertension. **2015**, 45-57
- 263 The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease. **2015**, 181-189
- 262 Methods of sympathetic activity evaluation in patients with systemic refractory hypertension. **2014**, 11, 21-26
- 261 Resistant Hypertension: Definition, Prevalence, and Therapeutic Approaches. **2015**, 903-917
- 260 Antihypertonika. **2015**, 451-475
- 259 Anatomy, Physiology and Pathophysiology of Renal Circulation. **2015**, 3687-3714
- 258 ??????????????????. **2015**, 23, 239-246
- 257 Calciumantagonisten. **2015**, 569-578
- 256 Arterial Hypertension. **2015**, 115-131
- 255 Profound sustained hypotension following renal denervation: a dramatic success?. **2015**, 105, 202-4 0
- 254 Radiofrequency renal arteries denervation: waiting for reply. **2015**, 12, 8-9 1

- 253 [Position paper on the results of Symplicity HTN-3 trial. Grupo de estudio de la hipertensi3 arterial resistente]. **2015**, 85, 154-7
- 252 Nuovo Approccio nel Trattamento Dell'ipertensione Arteriosa Resistente Mediante Anastomosi Artero-venosa. **2015**, 27, 67-69
- 251 Initial experience with therapeutic geometric modification of the carotid bulb for true resistant hypertension. **2015**, 11, 117-20 2
- 250 Radiofrequency denervation of renal arteries. Myth or reality?. **2015**, 12, 39-44 2
- 249 Management of the Hypertensive Child. **2016**, 2023-2097
- 248 Introduction. **2016**, 3-9
- 247 Efficacy of Renal Denervation on Blood Pressure Reduction. **2016**, 245-265
- 246 Safety of Renal Denervation. **2016**, 231-243
- 245 Devices to Treat Hypertension in Chronic Kidney Disease. **2016**, 321-339
- 244 Heart and Autonomic Nervous System : Learn from the Past, Create the Future. **2016**, 36, 315-327
- 243 Catheter Ablation Targeting Autonomic Nerves in the Treatment of Atrial Fibrillation. **2016**, 36, 344-353
- 242 Antihypertonika. **2016**, 335-350
- 241 Resistant Hypertension: A Real Entity Requiring Special Treatment?. **2016**, 11, 8-11
- 240 Interventional Therapies for Resistant Hypertension: A Brief Update. **2016**, 11, 65-69 0
- 239 Alternative Methods for Renal Denervation. **2016**, 321-337
- 238 Calciumantagonisten. **2016**, 413-419
- 237 Renal Sympathetic Denervation. **2016**, 455-458
- 236 Procedural Aspects of Renal Sympathetic Denervation. **2016**, 215-230

- 235 Radiofrequency renal arteries denervation: effectively and safely. **2016**, 13, 13-18
- 234 FIRE AND ICE: The quest for the perfect modality in atrial fibrillation ablation. **2016**, 2016, e201623 2
- 233 Renal denervation in the most serious form of resistant arterial hypertension. **2016**, 65, 909-916 1
- 232 Combined Drugs and Procedure Trials. **2017**, 371-379
- 231 Using a Placebo or Sham Procedure as a Control: Ethics and Practicalities. **2017**, 251-257
- 230 Kardialer Check-up. **2017**, 311-350
- 229 Calciumantagonisten. **2017**, 417-423
- 228 Antihypertonika. **2017**, 335-351
- 227 Hypertension in the Elderly. **2017**, 1-10
- 226 Renal denervation for treatment of hypertension - will 2017 be the year of enlightenment?. **2017**, 12, e2163-e2165
- 225 The role of the interventionalist in peripheral vascular interventions. **2017**, 611-626
- 224 Chemical renal denervation: an effective method to treat resistant hypertension?. **2017**, 13, e1129-e1130
- 223 Chemical sympathetic denervation: promising, but important distinctions between agents and methods. **2017**, 13, e1131-e1132
- 222 Obesity and Metabolic Syndrome Hypertension. **2018**, 705-722 3
- 221 Renal Denervation: Paradise Lost? Paradise Regained?. **2018**, 12, 78 1
- 220 Place of Invasive Procedures in Blood Pressure Control. **2018**, 853-865
- 219 Impact of Drug Adherence in Clinical Trials. **2018**, 145-151
- 218 Antihypertonika. **2018**, 385-400

217	The role of intervention methods of treatment of patients with resistant hypertension in contemporary cardiology. 2018 , 13, 22	1
216	Calciumantagonisten. 2018 , 467-473	
215	Arterielle Hypertonie. 2018 , 23-54	
214	The year in cardiology 2017: prevention. 2018 , 13, 79-98	
213	ENDOVASCULAR TREATMENT OF THE RESIDUAL THROMBOEMBOLIC PULMONARY HYPERTENSION AFTER PULMONARY THROMBENDARTERECTOMY WITH THE DENERVATION SYSTEM SYMPLICITY. 2018 , 17, 43-48	2
212	Reduction of Blood Pressure Following After Renal Artery Adventitia Stripping During Total Nephroureterectomy: Potential Effect of Renal Sympathetic Denervation. 2018 , 19, 567-572	1
211	Cardiovascular Outcomes and Potential Long-term Benefits of Renal Denervation in Patients with Resistant Hypertension. 2018 , 13, 277-282	1
210	The revival of catheter-based renal denervation?. 2018 , 17, 159-163	
209	Renal artery denervation: a lot done and more to do. 2018 , 14, e1252-e1254	1
208	Antihypertonika. 2019 , 513-529	
207	Calciumantagonisten. 2019 , 613-621	
206	Modern Aspects of Hypertensive Angioretinopathy. 2019 , 15, 470-475	0
205	Renal Denervation in High-risk Patients with Hypertension. 2019 , 13, 12	
204	Renal sympathetic denervation in resistant arterial hypertension: long term and updated results. 2019 , 68, 129-133	1
203	Achieving control of resistant hypertension: Not just the number of blood pressure medications. 2019 , 9, 1-16	
202	TREATMENT OF STABLE ISCHEMIC HEART DISEASE: IS CORONARY STENTING SUPERIOR OVER DRUG THERAPY?. 2019 , 26, 196-208	
201	[Selection of Patients with Resistant Arterial Hypertension for the Catheter-Based Renal Sympathetic Denervation]. 2019 , 59, 21-25	1
200	Management of Resistant Hypertension Based on Recommendations from Different Guidelines and the Systolic Blood Pressure Intervention Trial. 2019 , 11, e5371	2

- 199 Pathophysiology of Cardio-Renal Syndrome: Autonomic Mechanisms. **2020**, 35-50
- 198 Complex assessment of blood pressure regulation system in hypertension patients. **2019**, 5, 1-9
- 197 Renal denervation: bleak past, brighter future. **2019**, 30, 249-250
- 196 Renal denervation: dark past, bright future?. **2019**, 30, 290-296 0
- 195 Home Blood Pressure Monitoring in Clinical Research. **2020**, 89-101
- 194 Renal denervation in the treatment of resistant hypertension: a new dawn?. **2019**, 18, 143-148
- 193 Norepinephrine turnover in the left ventricle of subtotaly nephrectomized rats. **2019**, 68, S233-S242 1
- 192 Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure. **2020**, 13, 83-87 1
- 191 Renal sympathetic denervation for resistant hypertension: where do we stand after more than a decade. **2020**, 42, 67-76 4
- 190 Mechanism and Pathophysiology. **2020**, 19, 43-57
- 189 Los registros de denervaci3n renal, ¿completan la evidencia?. **2020**, 73, 605-607
- 188 Patients' attitude towards a sham-controlled trial on pulmonary vein isolation in atrial fibrillation. **2021**, 1 0
- 187 Diagnosis and treatment of arterial hypertension 2021. **2021**, 5
- 186 The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug. **2021**, 30, 327-331 1
- 185 [Ophthalmic aspects of vascular and functional changes in malignant arterial hypertension of renal origin]. **2020**, 136, 324-332 0
- 184 Renal Denervation: Physiology, Scope, and Current Evidence. **2020**, 349-366
- 183 Consensus paper on the evaluation and treatment of resistant hypertension by the Turkish Society of Cardiology. **2020**, 24, 137-152 0
- 182 Renal denervation: a new life of the technology. **2020**, 5, 117-125

- 181 Cardiovascular autonomic nervous system dysfunction in chronic kidney disease and end-stage kidney disease: disruption of the complementary forces. **2021**, 30, 198-207 0
- 180 Is There Role for Device Therapies in Resistant Hypertension? PRO.. **2020**, 1, 6-8
- 179 Monte Carlo Simulation for Trial Design Tool. **2020**, 1-23
- 178 ARTERIELLE HYPERTONIE. **2020**, F-1-F1-6
- 177 Shifting from Pharmacotherapy to Prevention of Hypertension. **2020**, 2, 33 0
- 176 Is There a Role for Device Therapies in Resistant Hypertension?: The CON Side.. **2020**, 1, 9-13 0
- 175 Antihypertonika. **2020**, 379-394
- 174 Calciumantagonisten. **2020**, 473-480
- 173 Animal model evaluation of a novel renal denervation system for future laparoscopic treatment of resistant hypertension. **2020**, 61, 107-113 2
- 172 Current and Emerging Therapies for Atherosclerosis. **2020**, 71-88
- 171 Nonpharmacological therapies for uncontrolled hypertension. **2020**, 1039-1064
- 170 Meta-analysis in renal denervation - Or how to compare apples with oranges?. **2021**, 34, 119-119 1
- 169 Systematic review of renal denervation for the management of cardiac arrhythmias. **2021**, 1 0
- 168 Renal Denervation for Hypertension: A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials. **2021**, 14, 2614-2624 6
- 167 Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage. **2022**, 79, 261-270 0
- 166 [New opportunities of renal denervation]. **2020**, 92, 84-88 2
- 165 Bilateral Nephrectomy, the Forgotten Measure in the Treatment of Refractory Hypertension in Patients With End-Stage Renal Disease: A Case Report and Literature Review. **2020**, 12, e9031 1
- 164 Distal renal denervation: cardioprotection in patients with resistant hypertension. **2020**, 19, 2225 2

- 163 A Pilot Study of Perioperative External Circumferential Cryoablation of Human Renal Arteries for Sympathetic Denervation. **2020**, 36, 151-157 2
- 162 Effects of different ablation points of renal denervation on the efficacy of resistant hypertension. **2020**, 8, e9842
- 161 Monte Carlo Simulation for Trial Design Tool. **2021**, 1-23
- 160 Renal denervation [not an easy road to treatment of arterial hypertension and concomitant diseases. **2020**, 3, 35-41
- 159 Effect of percutaneous renal sympathetic nerve radiofrequency ablation in patients with severe heart failure. **2015**, 8, 9779-85 9
- 158 Sympathetic renal denervation in hypertension with chronic kidney disease: a case report and review of literature. **2015**, 8, 16858-62 1
- 157 Intervention of Collective Exercise on the Mental Health of Elderly Hypertensive Patients. **2016**, 45, 314-21 4
- 156 Experimental Evidence Of The Role Of Renal Sympathetic Denervation For Treating Atrial Fibrillation. **2014**, 7, 1128 0
- 155 Renal Denervation And Pulmonary Vein Isolation In Patients With Drug Resistant Hypertension And Symptomatic Atrial Fibrillation. **2014**, 7, 1165 1
- 154 Control Of Hypertension Improves The Outcome Of Therapies For Paroxysmal And Persistent Atrial Fibrillation. **2014**, 7, 1092
- 153 Chemical renal artery denervation with appropriate phenol in spontaneously hypertensive rats. **2018**, 15, 695-702 1
- 152 Long-term renal sympathetic denervation ameliorates renal fibrosis and delays the onset of hypertension in spontaneously hypertensive rats. **2018**, 10, 4042-4053 12
- 151 Effect of Radiofrequency-Based Renal Denervation: The Impact of Unplanned Medication Change from a Systematic Review and Meta-Analysis. **2019**, 35, 144-152 3
- 150 The Far Eastern View on Renal Denervation - A Trailblazer for the Rest of the World. **2019**, 35, 231-233
- 149 Renal denervation in patients with symptomatic chronic heart failure despite resynchronization therapy - a pilot study. **2019**, 15, 240-246 3
- 148 Efficacy and Safety of Renal Denervation for Patients with Uncontrolled Hypertension in Taiwan: 3-Year Results From the Global SYMPLICITY Registry-Taiwan (GSR-Taiwan). **2019**, 35, 618-626 4
- 147 Resistant Hypertension: Where are We Now and Where Do We Go from Here?. **2020**, 13, 83-93 1
- 146 Renal Innervation in Resistant Hypertension: A Review of Pathophysiology and Renal Denervation as Potential Treatment. **2020**, 16, 115-127

- 145 Extended-Release Carvedilol in the Treatment of Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial. **2021**, 37, 186-194
- 144 Clinical trials with electromagnetic ablation technologies. **2022**, 381-397
- 143 Renal denervation therapy for hypertension: truths and half-truths: Renal denervation therapy for hypertension.. **2021**, 7, 62-68
- 142 Treatment-resistant hypertension assessed by home blood pressure monitoring: a new target for intervention?. **2021**, 1
- 141 Renal denervation for resistant hypertension. **2021**, 11, CD011499 3
- 140 sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation. **2021**, 11, 11130 1
- 139 Renal denervation ameliorates cardiac metabolic remodeling in diabetic cardiomyopathy rats by suppressing renal SGLT2 expression. **2021**,
- 138 Calciumkanalblocker. **2021**, 379-387
- 137 [Endovascular renal denervation for drug-refractory hypertension : RADIANCE-HTN TRIO].. **2022**, 63, 129-132
- 136 Renal Innervation in Resistant Hypertension: A Review of Pathophysiology and Renal Denervation as Potential Treatment. **2020**, 16, 115-127 0
- 135 Renal denervation- its current status & future prospects for management of Hypertension. **2020**, 019-021
- 134 Prenatal Programmed Adult-onset Salt Sensitive Hypertension. **2020**, 109, 2191-2198
- 133 Device-Based Treatment in Hypertension: At the Forefront of Renal Denervation. **2021**, 1, 112-127
- 132 Recruitment for placebo-controlled trials of interventional procedures: a patient-centred approach.. **2021**, 17, e963-e965
- 131 [Renal denervation : Really an alternative to reducing blood pressure?]. **2022**, 63, 330
- 130 Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial.. **2022**, 8, e08747
- 129 Effectiveness of radiofrequency renal denervation in diseases with increased sympathetic nervous system activity. **2022**, 20, 3139
- 128 Safety and efficacy of renal denervation in patients with heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis.. **2022**, 8, e08847 1

- 127 Estimating the sample size of sham-controlled randomized controlled trials using existing evidence. 11, 85
- 126 Morphometric analysis of the human common hepatic artery reveals a rich and accessible target for sympathetic liver denervation.. **2022**, 12, 1413
- 125 Renal denervation for the treatment of hypertension. Back and stronger. **2022**,
- 124 Carotid Implants to Treat Resistant Arterial Hypertension: A Paradigm for the Collaboration Between Clinicians and Interventionalists.. **2022**, 15, 333-335 0
- 123 Effects of renal denervation on sleep apnea and arrhythmia in rats with myocardial infarction.. **2022**, 91, 115-123
- 122 Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study.. **2022**, 15, 321-332 0
- 121 Beyond the Anatomy of Renal Nerves: Functional Diversity of Renal Nerves.. **2022**, 15, 27
- 120 Time, temperature, power, and impedance considerations for radiofrequency catheter renal denervation.. **2022**, 2
- 119 Fire or Ice: Cryoablation as a Viable Alternative to Radiofrequency Ablation for Renal Artery Denervation?. **2022**, 7, 113-115
- 118 Dynamics of Soluble Factors and Double-Negative T Cells Associated with Response to Renal Denervation in Resistant Hypertension Patients.. **2022**, 12, 1
- 117 Experience of using multielectrode catheter systems to perform radiofrequency renal sympathetic denervation in patients with resistant hypertension: immediate procedural effects. **2022**, 27, 4794 0
- 116 Acute and Short-Term Autonomic and Hemodynamic Responses to Transcranial Direct Current Stimulation in Patients With Resistant Hypertension.. **2022**, 9, 853427 0
- 115 Advances in the Treatment Strategies in Hypertension: Present and Future.. **2022**, 9, 0
- 114 What We Know and Don't Know About Renal Denervation to Lower Blood Pressure.. **2022**, 0
- 113 Rethinking Resistant Hypertension.. **2022**, 11, 2
- 112 Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. **2022**, 145, 847-863 3
- 111 Long-term outcome of renal nerve denervation (RDN) for resistant hypertension.. **2022**, 0
- 110 Intravascular Renal Denervation Reduces Ambulatory and Office Blood Pressure in Patients with Essential Hypertension: A Meta-Analysis of Randomized Sham-Controlled Trials.. **2022**, 1

109	An Update on Refractory Hypertension.. 2022 , 1	1
108	Consideration regarding the Analysis of Randomized Controlled Trials in the era of Evidence-Based Medicine.. 2021 ,	0
107	Catheter-Based Renal Denervation Therapy: Evolution of Evidence and Future Directions.. 2021 , 14, e011130	
106	Real-world management and outcomes of 7 million patients with acute coronary syndrome according to clinical research trial enrollment status: A propensity matched analysis.. 2021 ,	0
105	Hypertension research from Japan: advancing the field of renal denervation. 2021 ,	0
104	Renal denervation: basic and clinical evidence.. 2021 ,	1
103	Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases.. 2021 , 8, 803984	1
102	Cardiovascular risk prevention in clinical medicine: current guidelines in the United States and in Europe. 2022 , 471-490	
101	Renale Denervation [Phoenix aus der Asche. 2022 , 11, 154-160	
100	Effectiveness of renal denervation in the treatment of hypertension: a literature review.. 2022 , 28, 11	1
99	Data_Sheet_1.docx. 2020 ,	
98	[Renal sympathetic denervation can significantly reduce blood pressure and improve arterial stiffness in hypertensive beagles].. 2021 , 41, 1609-1615	
97	Resistant Hypertension: Where are We Now and Where Do We Go from Here?. 2020 , Volume 13, 83-93	5
96	Resistant Hypertension: Recognition and Treatment. 2022 , 351-366	
95	Hypertension in the Elderly: Pathophysiology and Clinical Significance. 2022 , 239-256	0
94	Mechanical Interventional Therapies for Hypertension: Present Status and Future Prospects. 2022 , 381-394	
93	Impacto de las terapias alternativas en el tratamiento de la hipertensi3n arterial sist3nica resistente. 2022 , 33, 233-237	
92	Renal denervation in resistant hypertension: a review of clinical trials and future perspectives.. 2022 , 1	

91	Patient Selection for Renal Denervation in Hypertensive Patients: What Makes a Good Candidate?. 2022 , 18, 375-386	3
90	Lifestyle Modification and Atrial Fibrillation: Critical Care for Successful Ablation.. 2022 , 11,	1
89	Renal Denervation for Resistant Hypertension. 2022 , 520-528	
88	The sham effect of invasive interventions in chronic coronary syndromes: a systematic review and meta-analysis.. 2022 , 22, 223	
87	Renal denervation in patients with chronic kidney disease: current evidence and future perspectives.	0
86	Tratamiento endovascular de las lesiones de las arterias renales. 2022 , 22, 1-14	
85	Renal Denervation: A Review. 2022 ,	0
84	Hypertension and the kidneys. 2022 , 83, 1-11	1
83	2022 Malaysian Working Group Consensus Statement on Renal Denervation for management of arterial hypertension.	1
82	Long lasting effects of renal denervation: lights and shadows of the SPYRAL HTN-ON MED 3-year follow-up.	
81	Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.	1
80	Renal denervation for hypertension: A new meta-analysis promotes further discussion. 2022 ,	0
79	Renal Sympathetic Denervation for Hypertension. 2022 ,	1
78	Update on Hypertension Research in 2021. 2022 , 45, 1276-1297	1
77	Catheter-based renal sympathetic nerve denervation on hypertension management outcomes. 2022 , 14, 238-248	
76	Predicting Renal Denervation Response in Resistant High Blood Pressure by Arterial Stiffness Assessment: A Systematic Review. 2022 , 11, 4837	1
75	The position of renal denervation in treatment of hypertension: an expert consensus statement.	
74	Neuromodulation Therapy for Atrial Fibrillation. 2022 ,	0

73	Renal Denervation for Resistant Hypertension: A Concise Update on Treatment Options and the Latest Clinical Evidence. 2022 , 11, 385-392	
72	Present Evidence of Determinants to Predict the Efficacy of Renal Denervation. 2022 , 2022, 1-12	2
71	Renal denervation in the antihypertensive arsenal [knowns and known unknowns]. 2022 , 40, 1859-1875	0
70	Citri Reticulatae Pericarpium (Chenpi): A multi-efficacy pericarp in treating cardiovascular diseases. 2022 , 154, 113626	0
69	Monte Carlo Simulation for Trial Design Tool. 2022 , 1563-1585	0
68	Pathophysiology and Epidemiology of Hypertension in Children. 2022 , 1477-1510	0
67	Consensus and inconsistency between different consensus documents on renal denervation worldwide: the way forward. Publish Ahead of Print,	0
66	SYMPPLICITY HTN-3: failure at 6 months, success at 3 years?. 2022 ,	0
65	Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.	1
64	Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPPLICITY HTN-3 Trial. 2022 ,	4
63	The impact of renal denervation procedure on use of antihypertensive drugs in the real-life setting. 2022 , 31, 245-253	0
62	Highlights of the 2022 Vietnamese Society of Hypertension guidelines for the diagnosis and treatment of arterial hypertension. 2022 , 24, 1121-1138	1
61	Arterial hypertension and atrial fibrillation: general pathogenesis and mutual effects on the course of diseases. 2022 , 100, 253-260	0
60	Interventional Therapy in Refractory Hypertension: An Update. 2022 ,	0
59	The role of renal nerve stimulation in percutaneous renal denervation for hypertension: A mini-review. 2022 , 24, 1187-1193	1
58	Renale Denervation mittels Radiofrequenzablation.	0
57	Device-Based Therapy for Resistant Hypertension: An Up-to-Date Review.	0
56	The HOPE Asia network 2022 up-date consensus statement on morning hypertension management. 2022 , 24, 1112-1120	1

55	Novel therapies on the horizon of hypertension management.	0
54	The intrarenal blood pressure modulation system is differentially altered after renal denervation guided by different intensities of blood pressure responses.	1
53	Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. 2022 , 18, e677-e685	0
52	Anatomical Evidence for Parasympathetic Innervation of the Renal Vasculature and Pelvis. ASN.2021111518	0
51	Use of a bio-electronic device comprising of targeted dual neuromodulation of the hepatic and celiac vagal branches demonstrated enhanced glycemic control in a type 2 diabetic rat model as well as in an Alloxan treated swine model. 16,	0
50	Effect of Concomitant Renal DeNervation and Cardiac Ablation on Atrial Fibrillation recurrence □ RDN+AF Study.	0
49	Transurethral Renal Pelvic Denervation: A Feasibility Trial in Patients with Uncontrolled Hypertension.	0
48	Advances in pathogenesis and treatment of essential hypertension. 9,	1
47	Effect of extensive artery isolation during robotic-assisted partial nephrectomy on blood pressure of patients with poorly controlled hypertension: a preliminary study.	0
46	A Systematic Review of Patient Preferences, Expectations, and Values for the Management and Treatment of Hypertension. Volume 16, 2867-2876	1
45	Hypertension in chronic kidney disease: What lies behind the scene. 13,	2
44	Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes. 2022 , 206, 115304	0
43	The role of the sympathetic nervous system in resistant hypertension: pathophysiological and clinical aspects. 2022 , 28, 348-356	0
42	Differences in the effectiveness of sympathetic radiofrequency denervation of the renal arteries in patients with resistant arterial hypertension and hyperuricemia. 2022 , 28, 428-443	0
41	Endothelin antagonists and the quest for a new therapeutic option in resistant hypertension. 2022 ,	0
40	The Rise and Fall and Rise of Renal Denervation. 2022 , 80, 1881-1883	0
39	The enigma of resistant hypertension: from lifestyle changes and pharmacological treatment to renal denervation. 2022 , 24, 1197-1200	0
38	Estimating the sample size of sham-controlled randomized controlled trials using existing evidence. 11, 85	0

- 37 Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation. ○
- 36 Hypertension. **2022**, 329-353 ○
- 35 Chronic Kidney Disease and Hypertension. **2022**, 573-588 ○
- 34 Pharmacotherapy for Essential Hypertension: A Brief Review. **2022**, 18, 5-16 ○
- 33 Emerging drugs for the treatment of diabetic nephropathy. **2022**, 27, 417-430 ○
- 32 Uncontrolled hypertension and obstructive sleep apnea: integrated treatment approach. **2022**, 19, 41-47 ○
- 31 Catheter-based renal denervation in Chinese patients with chronic kidney disease and uncontrolled hypertension. ○
- 30 The role of immune-inflammatory mechanisms in the pathogenesis of hypertension. ○
- 29 Effects of renal denervation on endogenous ouabain in spontaneously hypertensive rats. **2022**, 37, ○
- 28 Role Renin Angiotensin System in Hypertension. **2023**, 187-200 ○
- 27 Role of renal sympathetic denervation in non-pharmacological treatment of cardiovascular diseases. **2022**, 21, 208-215 ○
- 26 Influence of catheter-based renal denervation on carbohydrate metabolism in patients with diabetes and hypertension. **2023**, 21, 3459 ○
- 25 A Subgroup Meta-Analysis Comparing the Renal Denervation Sham-Controlled Randomized Trials Among Those With Resistant and Nonresistant Hypertension. **2023**, 191, 119-124 ○
- 24 Hypertension in Chronic Kidney Disease: An Update on Diagnosis and Management. **2023**, 116, 237-244 ○
- 23 Renal nerve stimulation identifies renal innervation and optimizes the strategy for renal denervation in canine. **2023**, 21, ○
- 22 2022 Renal denervation therapy for the treatment of hypertension: a statement from the Thai Hypertension Society. **2023**, 46, 898-912 ○
- 21 Aerobic exercise improves central blood pressure and blood pressure variability among patients with resistant hypertension: results of the EnRicH trial. ○
- 20 Peregrine system infusion catheter for neurolytic renal denervation in hypertension: an overview of its safety and efficacy. **2023**, 20, 179-186 ○

- 19 Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials. ○
- 18 Is There a Role for Renal Denervation in the Treatment of Hypertension?. ○
- 17 Endovascular Ultrasound Renal Denervation to Treat Hypertension. **2023**, 329, 651 ○
- 16 Effect of focused power ultrasound mediated perirenal fat modification on primary hypertension: protocol of a multicenter, randomized, double-blinded, sham-controlled study. ○
- 15 Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension. **2023**, 13, 806 ○
- 14 Effect of focused power ultrasound-mediated perirenal fat modification on primary hypertension: protocol of a multicenter, randomized, double-blinded, sham-controlled study. **2023**, 24, ○
- 13 Effect of renal denervation for patients with isolated systolic hypertension: a systematic review and meta-analysis. **2023**, 20, 121-129 ○
- 12 Emerging topics on renal denervation in hypertension: anatomical and functional aspects of renal nerves. ○
- 11 Advances in Renal Denervation in the Treatment of Hypertension. **2023**, 7, ○
- 10 Hypertension and the metabolic syndrome: toward personalized management. **2023**, 397-425 ○
- 9 Interventionelle Therapie der arteriellen Hypertonie. **2023**, 23, 23-29 ○
- 8 The role of immune-inflammatory mechanisms in the pathogenesis of hypertension. **2023**, 38, 21-27 ○
- 7 Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. **2023**, 8, ○
- 6 Key questions regarding the SYMPPLICITY HTN-3 trial [Authors' reply]. **2023**, 401, 1337-1338 ○
- 5 Renal denervation and long-term results. **2023**, 25, B85-B89 ○
- 4 Review of late-breaking trials from CRT 2023. **2023**, ○
- 3 Devices for the treatment of arterial hypertension. **2023**, 77, 27-35 ○
- 2 Predictors for success of renal denervation in patients with resistant arterial hypertension. **2023**, 29, 175-185 ○

- 1 The Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral and Central Hemodynamic Parameters on Resistant Hypertension: A Case Report. Volume 19, 317-323

o